
Biotechnological production
of 3-hydroxyisobutyric acid

The invention relates to a method comprising the steps a) providing isobutyric acid, b) bringing
5 isobutyric acid into contact with the combination of isobutyrate kinase and
phosphotransisobutyrylase and/or isobutyryl-coenzyme A synthetase/ligase and/or isobutyrate-
coenzyme A transferase, c) bringing the product from step b) into contact with isobutyryl-
coenzyme A dehydrogenase, d) bringing the product from step c) into contact with methacrylyl-
coenzyme A hydratase, and e) hydrolyzing of the product from step d) to form 3-
10 hydroxyisobutyric acid, where at least one of the enzymes is provided in the form of a cell,
which, compared to its wildtype, comprises a reduced activity of a 3-hydroxyisobutyric acid
dehydrogenase or a variant thereof, a cell which has at least one enzyme from the group
comprising isobutyryl-coenzyme A synthetase/ligase, isobutyrate-coenzyme A transferase,
isobutyrate kinase, phosphotransisobutyrylase, isobutyryl-coenzyme A dehydrogenase,
15 methacrylyl-coenzyme A hydratase and 3-hydroxyisobutyryl-coenzyme A hydrolase and,
compared to its wildtype, a reduced activity of a 3-hydroxyisobutyric acid dehydrogenase or a
variant thereof, wherein the cell preferably has, in addition, a monooxygenase, more preferably
an alkane hydroxylase of the alkBGT type or a variant thereof and the use of such a cell for
preparing 3-hydroxyisobutyric acid.

20
Methacrylic acid constitutes one of the most important industrially produced chemicals. In the
form of its monomeric methyl ester, it is required as a polymerisation reactant for preparing
polymethyl methacrylate, being known to the public under the trade name Plexiglas, and is
indispensable in many areas of application. Examples of the use of polymethacrylate include
25 dentistry, where it is used for prostheses, the automotive industry, in which it is used as the
glass for indicator and tail lights, optics, in particular as a material for contact lenses and
spectacle glass, the building trade, where it is used as polymer concrete and also as a two-
component adhesive, the textile industry as a constituent of polyacrylic fibres, and in the
domestic home as a material for items such as dishes and cutlery.

Methacrylic acid is conventionally prepared starting from fossil raw materials such as oil. For example, isobutylene and tertiary butanol can be converted to methacrolein, which is then further oxidised to methacrylate (William Bauer, Jr. "Methacrylic Acid and Derivatives" in Ullmann's Encyclopedia of Industrial Chemistry 2002, Wiley-VCH, Weinheim). Alternatively, 5 amidosulphates of methacrylic acid, which are produced starting from the corresponding 2-hydroxynitriles, can be hydrolysed to form methacrylic acid. The industrial production of methacrylic acid using such methods depends however not only on a continuous supply of fossil reactants, but also takes place with the consumption of considerable quantities of aggressive, environmentally harmful chemicals. For example, the production of 1 kg of methacrylic acid by 10 hydrolysis of amidosulphates of methacrylic acid requires 1.6 kg of sulphuric acid.

In order to overcome the dependence on fossil raw materials as a source of energy and reactants for industrial syntheses, diverse efforts are currently being adopted, which are aimed at producing industrially required fine chemicals biotechnologically on the basis of renewable 15 raw materials. In the case of methacrylic acid and the respective methyl ester, a biotechnological synthesis route via 3-hydroxyisobutyric acid, which can be readily dehydrated chemically or enzymatically to form methacrylic acid, is suitable (William Bauer, Jr. "Methacrylic Acid and Derivatives" in Ullmann's Encyclopedia of Industrial Chemistry 2002, Wiley-VCH, Weinheim). The prior art teaches the preparation of 3-hydroxyisobutyric acid from isobutyric 20 acid using wildtype isolates of bacteria and yeasts (Hasegawa *et al.*, 1981; Hasegawa *et al.*, 1982, WO 2007/141208 A2 und WO 2008/119738 A1). Isobutyric acid is used exclusively as the substrate for preparing 3-hydroxyisobutyric acid by suitable strains, for example by *Candida rugosa*. The abovementioned patent applications, WO 2007/141208 A2 and WO 2008/119738 A1, describe a genetically modified cell and method for preparing 3-hydroxyisobutyric acid from 25 carbohydrates, glycerol, carbon dioxide, methanol, L-valine, L-glutamate, CO, synthesis gas, methane etc. and also its further chemical conversion to methacrylic acid or methacrylic acid esters.

The preparation of 3-hydroxyisobutyric acid via the biotechnological methods described above 30 is currently however uneconomical. A significant drawback here is the high raw material costs for isobutyric acid and, concomitantly, at times the low yield during their conversion or use of appropriate microorganisms.

Against this background, it is the object of the present invention to develop an improved method for the biotechnological preparation of 3-hydroxyisobutyric acid, which is superior to the methods described in the prior art with regard to yield, purity and the resources required.

- 5 Furthermore, the object of the present invention consists in developing a biotechnological method for preparing 3-hydroxyisobutyric acid starting from unsubstituted, particularly non-heteroatom-containing, alkanes.

10 Furthermore, the object of the present invention is to develop a biotechnological method for obtaining 3-hydroxyisobutyric acid starting from renewable raw materials and/or without the use of, or with less use of, harmful reactants, intermediates, catalysts or by-products.

These and other objects are achieved by the subject matter of the present application and particularly also by the subject matter of the accompanying independent claims, with
15 embodiments arising from the dependent claims.

The object is achieved according to the invention in a first aspect by a method comprising the following steps:

20

a) providing isobutyric acid,

b) bringing isobutyric acid into contact with

25

the combination of isobutyrate kinase and phosphotransisobutyrylase and/or

isobutyryl-coenzyme A synthetase/ligase and/or

isobutyrate-coenzyme A transferase,

30

c) bringing the product from step b) into contact with isobutyryl-coenzyme A dehydrogenase,

d) bringing the product from step c) into contact with methacrylyl-coenzyme A hydratase, and

e) hydrolyzing the product from step d) to form 3-hydroxyisobutyric acid,

5

wherein at least one of the enzymes used in the steps b), c) and d) from the group comprising isobutyrate kinase, phosphotransisobutyrylase, isobutyryl-coenzyme A synthetase/ligase and isobutyrate-coenzyme A transferase, preferably all, enzymes is used in the form of a cell, which, compared to its wildtype, has a reduced activity of a 3-

10

hydroxyisobutyric acid dehydrogenase or a variant thereof.

In a first embodiment of the first aspect, the isobutyric acid is formed by bringing isobutane into contact with a monooxygenase, preferably an alkane hydroxylase, more preferably one of the alkBGT type or a variant thereof.

15

In a second embodiment of the first aspect, which also constitutes an embodiment of the first embodiment, the hydrolysis in step e) is achieved by bringing the product from step d) into contact with a 3-hydroxyisobutyryl-coenzyme A hydrolase.

20

In a third embodiment of the first aspect, which also constitutes an embodiment of the first and second embodiment, the cell has both the isobutyryl-coenzyme A dehydrogenase in step c) and the methacrylyl-coenzyme A hydratase in step d) and

the combination of isobutyrate kinase and phosphotransisobutyrylase and/or

25

isobutyryl-coenzyme A synthetase/ligase and/or

isobutyrate-coenzyme A transferase.

30

In a fourth embodiment of the first aspect, which also constitutes an embodiment of the first to third embodiment, the cell additionally has an alkane hydroxylase, preferably one of the alkBGT type or a variant thereof.

In a fifth embodiment of the first aspect, which also constitutes an embodiment of the first to fourth embodiment, the 3-hydroxyisobutyric acid dehydrogenase is XP_504911.1 or a variant thereof.

5 The object in a second aspect is achieved, according to the invention, by a cell which has at least one enzyme from the group comprising isobutyryl-coenzyme A synthetase/ligase, isobutyrate-coenzyme A transferase, isobutyrate kinase, phosphotransisobutyrylase, isobutyryl-coenzyme A dehydrogenase, methacrylyl-coenzyme A hydratase and 3-hydroxyisobutyryl-coenzyme A hydrolase and, compared to its wildtype, a reduced activity of a 3-
10 hydroxyisobutyric acid dehydrogenase or a variant thereof.

In a first embodiment of the second aspect the cell has, in addition to an isobutyryl-coenzyme A dehydrogenase, and in addition to a methacrylyl-coenzyme A hydratase,

15 the combination of isobutyrate kinase and phosphotransisobutyrylase and/or

isobutyryl-coenzyme A synthetase/ligase and/or

isobutyrate-coenzyme A transferase,

20

preferably furthermore a 3-hydroxyisobutyryl-CoA hydrolase.

In a second embodiment of the second aspect, which also constitutes an embodiment of the first embodiment, the cell further comprises an alkane hydroxylase, preferably one of the
25 alkBGT type or a variant thereof.

In a third embodiment of the second aspect, which also constitutes an embodiment of the first embodiment, the 3-hydroxyisobutyric acid dehydrogenase is Yali0F02607g (XP_504911) or a variant thereof.

30

In a third aspect the object of the present invention is achieved by using the cell according to any of Claims 7 to 10 for preparing 3-hydroxyisobutyric acid.

In one embodiment of the third aspect, the 3-hydroxyisobutyric acid dehydrogenase is XP_504911.1 or a variant thereof.

In a further embodiment of the first, second or third aspect, the cell is a bacterial or lower eukaryotic cell.

In a further embodiment of the first, second or third aspect, the cell is a yeast cell from the group of genera which comprises *Yarrowia*, *Candida*, *Saccharomyces*, *Schizosaccharomyces* and *Pichia* and is preferably *Yarrowia lipolytica*.

In a fourth aspect the object of the present invention is achieved by a reaction mixture comprising the cell according to the second aspect and also isobutane or isobutyric acid.

The inventors of the present invention have surprisingly established that the inactivation of a gene which codes for an enzyme identified as 3-hydroxyisobutyric acid dehydrogenase in a microorganism leads to an increased yield of 3-hydroxyisobutyric acid.

The inventors have further surprisingly found that it is possible to prepare 3-hydroxyisobutyric acid biotechnologically, starting from alkane reactants, particularly isobutane.

Conducting the method according to the invention initially requires the provision of isobutyric acid. Firstly, there is the option of using commercially available isobutyric acid. Secondly, there is the option to prepare isobutyric acid using isolated enzymes or whole organisms with suitable catalytic capability, starting from other reactants, for example by cultivation of an organism which naturally produces isobutyric acid. In a preferred embodiment, the isobutyric acid is prepared by bringing isobutane, or another suitable alkane precursor, into contact with a suitable monooxygenase, preferably alkane hydroxylase, which, in a particularly preferred embodiment, is an alkane hydroxylase of the alk-BGT type or a variant thereof. In a preferred embodiment, the term "alkane hydroxylase", as used here, is understood to mean an oxidoreductase which has the ability to oxidise saturated hydrocarbons, particularly isobutane or 3-hydroxyisobutane, to give the carboxylic acid, preferably at a terminal carbon atom. The prior art describes a series of suitable microorganisms and enzymes. For example, Patel *et al.* (Journal of Applied Biochemistry, 1983, 5 (1 - 2), 107 – 120) describe describe 16 new bacterial strains which have the ability to oxidise gaseous alkanes with a chain length of from C2 to C4 to

give the corresponding methyl ketones, secondary and primary alcohols and aldehydes. Grant *et al.* (2011) describe the oxidation of alkanes to corresponding acids by means of the alkB alkane hydroxylase (Grant, C, Woodley, J & Baganz, F 2011, 'Whole-cell bio-oxidation of n-dodecane using the alkane hydroxylase system of *P. putida* GPo1 expressed in *E. coli*', *Enzyme and Microbial Technology*, vol 48, no. 6-7, pp. 480-486).

On the other hand, there is the option to prepare isobutyric acid using suitable strains of microorganisms which, naturally or by genetic modification, are endowed with metabolic pathways which include producing isobutyric acid by feeding with suitable carbon sources, e.g. glucose. Examples of microorganisms include e.g. *Yarrowia lipolytica*, *Candida rugosa*, *Hanseniaspora valbyensis*, *Hansenula anomala*, *Trichosporon aculeatum*, *Trichosporon fennicum*, *Endomyces reessii*, *Geotrichum loubieri*, *Micrococcus flavus*, *Micrococcus luteus*, *Micrococcus lysodeikticum*, *Candida parapsilosis*, *Pichia membranaefaciens*, *Torulopsis candida*, *Coccidioides posadasii*, *Coccidioides immitis*, *Verticillium dahliae*, *Gibberella zeae*, *Thielavia terrestris*, *Metarhizium acridum*, *Magnaporthe oryzae*, *Sordaria macrospora*, *Metarhizium nisopliae*, *Ajellomyces dermatitidis*, *Chaetomium globosum*, *Paracoccidioides brasiliensis*, *Nectria haematococca*, *Neurospora tetrasperma*, *Chaetomium thermophilum* und *Neurospora crassa*.

In a preferred embodiment, the isobutyric acid is provided by oxidation of isobutane by the oxidoreductase alkB from the alkBGT system of *Pseudomonas putida* or a variant thereof. AlkB is an oxidoreductase from the alkBGT system of *Pseudomonas putida*, which is known for its alkane hydroxylase activity. This is dependent on two further polypeptides, alkG and alkT. AlkT is characterised as FAD-dependent rubredoxin reductase, which transfers electrons from NADH to alkG. AlkG is a rubredoxin, an iron containing redox protein, which functions as a direct electron donor for alkB. In a preferred embodiment, the term "alkane hydroxylase of the alkBGT type", as used here, is understood to mean a membrane-bound alkane monooxidase. In a further preferred embodiment the same term "alkane hydroxylase of the alkBGT type" is understood to mean a polypeptide with a sequence homology of, with increasing preference, at least 75, 80, 85, 90, 92, 94, 96, 98 or 99 % to the sequence of the alkB of *Pseudomonas putida* Gpo1 (data bank code: CAB54050.1). In a further preferred embodiment, the term is understood to mean a cytochrome-independent monooxygenase. In a further preferred embodiment, the term "alkane hydroxylase of the alkBGT type" is understood to mean a cytochrome-independent monooxygenase which uses a rubredoxin or homologue as electron donor. In a particularly

preferred embodiment, the term is understood to mean a membrane-bound, cytochrome-independent alkane monooxygenase of, with increasing preference, at least 60, 70, 80, 80, 85, 90, 92, 94, 96, 98 or 99 % to the sequence of the alkB of *Pseudomonas putida* Gpo1, which requires as electron donor at least alkG (CAB54052.1), but preferably the combination of alkG
5 with the reductase alkT (CAB54063.1), wherein alkG and/or alkT may also be a homologue of the respective polypeptide. The term "sequence", as used here, may refer to the amino acid sequence of a polypeptide and/or its nucleic acid coding sequence. In a further preferred embodiment, "an oxidoreductase of the alkB type", as used here, is a cytochrome-independent oxidoreductase, i.e. an oxidoreductase which does not include cytochrome as cofactor.

10 There is the option, for this purpose, to bring purified components of the alkBGT system into contact with isobutane, particularly alkB. In a preferred embodiment, isobutane is brought into contact with an alkBGT-containing whole-cell catalyst; in a most preferred embodiment expressed with a recombinant *E.coli* strain of the heterologous alkBGT.

15 The teaching of the present invention may be implemented not only by using the exact amino acid or nucleic acid sequences of the biological macromolecules described herein, but also by using variants of such macromolecules, which may be obtained by deletion, addition or substitution of one, or more than one, amino acids or nucleic acids. In a preferred embodiment,
20 the term "variant" of a nucleic acid sequence or an amino acid sequence, hereinbelow used synonymously and interchangeably with the term "homologue", as used here, means another nucleic acid or amino acid sequence which has an homology, here used synonymously with identity, of 70, 75, 80, 85, 90, 92, 94, 96, 98, 99 % or more percent, with respect to the corresponding original wildtype nucleic acid or amino acid sequence, wherein preferably the
25 amino acids other than the amino acids forming the catalytically active centre or essential for the structure or folding are substituted or deleted or the latter are merely conservatively substituted, for example a glutamate in place of an aspartate or a leucine in place of a valine. The prior art describes algorithms which may be used to calculate the degree of homology of two sequences, e.g. Arthur Lesk (2008), Introduction to Bioinformatics, 3rd edition. In a further
30 more preferred embodiment of the present invention, the variant of an amino acid or nucleic acid sequence, preferably in addition to the aforementioned sequence homology, has essentially the same enzymatic activity of the wildtype molecule and of the original molecule. For example, a variant of an enzymatically active protease polypeptide has the same, or essentially the same, proteolytic activity as the polypeptide enzyme, i.e. the capability to

catalyse the hydrolysis of a peptide bond. In a particular embodiment, the term "essentially the same enzymatic activity" means an activity, with respect to the substrates of the wildtype polypeptide, which clearly lies above the background activity and/or differs from the K_M and/or k_{cat} values by less than 3, preferably 2, more preferably one, order of magnitude, which the wildtype polypeptide exhibits with respect to the same substrates. In a further preferred embodiment the term "variant" of a nucleic acid or amino acid sequence includes at least one active part/ or fragment of the nucleic acid or amino acid sequence. In a further preferred embodiment, the term "active part", as used here, means an amino acid sequence or a nucleic acid sequence which has less than the full length of the amino acid sequence and/or codes for less than the full length of the amino acid sequence, wherein the amino acid sequence or the coded amino acid sequence with a shorter length than the wildtype amino acid sequence essentially has the same enzymatic activity as the wildtype polypeptide or a variant thereof, for example, alcohol dehydrogenase, monooxygenase or transaminase. In a particular embodiment, the term "variant" of a nucleic acid comprises a nucleic acid whose complementary strand, preferably under stringent conditions, binds to the wildtype nucleic acid. The stringency of the hybridisation reaction is readily determinable by those skilled in the art and depends in general on the length of the probe, the washing temperatures and the salt concentration. Generally, longer probes require higher temperatures for the hybridisation, whereas shorter probes work at lower temperatures. Whether hybridisation takes place depends in general on the capability of the denatured DNA to anneal to complementary strands which are present in its environment and below the melting temperature. The stringency of hybridisation reactions and the corresponding conditions are described in more detail in Ausubel *et al.* 1995. In a preferred embodiment, the term "variant" of a nucleic acid, as used here, comprises any nucleic acid sequence which codes for the same amino acid sequence as the original nucleic acid or a variant of this amino acid sequence in terms of the degeneracy of the genetic code.

After the provision of isobutyric acid, this is, according to the invention, brought into contact with an enzyme or enzyme system, which has the capability to convert it to isobutyryl-CoA. It is possible to bring isobutyric acid into contact with the combination of isobutyrate kinase and phosphotransisobutyrylase. The term "isobutyrate kinase", as used here, is understood to mean an enzyme which has the capability to phosphorylate isobutyric acid with hydrolysis of ATP. In a particularly preferred embodiment, the term "phosphotransisobutyrylase", as used here, is understood to mean an enzyme that catalyses the conversion of the phosphorylated

butyric acid to isobutyryl-CoA using coenzyme A. Those skilled in the art can find suitable enzymes in the prior art, for example: NP_348286.1, YP_001311072.1, YP_001311673.1, YP_003845108.1, CCC57671.1, ZP_02993103.1, YP_001255907.1, YP_001788766.1, YP_001783065.1, ZP_02613551.1, ZP_05129586.1, NP_783068.1, ZP_02616584.1, 5 YP_001392779.1, ZP_02642313.1, YP_697036.1, NP_563263.1, YP_699607.1, ZP_05129585.1, ZP_05394270.1, ZP_04821992.1, YP_001086582.1, YP_001884532.1, YP_001919732.1, YP_001513941.1, YP_001322041.1, NP_349675.1, YP_001307350.1, ZP_02074622.1, AAA75487.1, ZP_05979314.1, ZP_02950703.1, YP_003935519.1, YP_001126403.1, ZP_03147541.1, BAD11094.1, ZP_08532470.1, CBK83142.1, 10 ZP_02027123.1, ZP_02206646.1, ZP_03226899.1, ZP_05791023.1, YP_002950277.1, YP_003825217.1, ZP_08609344.1, YP_004819378.1, YP_001376086.1, ZP_06425397.1, ZP_04152833.1, ZP_03292064.1, ZP_07525976.1, YP_003477715.1, YP_001664465.1, ZP_04218902.1, YP_003677577.1, ZP_02211576.1, ZP_04187800.1, ZP_04302360.1, ZP_04098303.1, ZP_00394509.1, YP_085496.1, NP_846616.1, ZP_04313571.1, 15 YP_896508.1, NP_980529.1, ZP_04170515.1, YP_001646798.1, ZP_00240356.1, ZP_04269443.1, ZP_04291055.1, ZP_04176201.1, ZP_01860365.1, ZP_03237173.1, YP_001471381.1, ZP_08211979.1, ZP_04208847.1, YP_004820818.1, ZP_04103879.1, YP_003666354.1, NP_833876.1, ZP_04285820.1, ZP_04086212.1, ZP_04147476.1, NP_623752.1, ZP_03231885.1, ZP_04066826.1, ZP_08211238.1, ZP_07709086.1, 20 YP_002315321.1, YP_002447739.1, ZP_00741048.1, ZP_04073820.1, YP_003988617.1, YP_002368967.1, YP_148233.1, YP_003251443.1, AEN87678.1, YP_003564885.1, YP_004660977.1, YP_004587379.1, NP_349675.1, AAA75487.1, YP_001788766.1, YP_001255907.1, ZP_02993103.1, YP_001783065.1, ZP_02613551.1, ZP_02616584.1, YP_001392779.1, ZP_05394270.1, NP_783068.1, CCC57671.1, YP_697036.1, NP_563263.1, 25 YP_699607.1, ZP_02642313.1, YP_001919732.1, ZP_07525976.1, YP_001884532.1, ZP_04821992.1, ZP_03292064.1, ZP_05129586.1, YP_001307350.1, ZP_02950703.1, ZP_05129585.1, YP_001086582.1, YP_001311072.1, YP_001513941.1, YP_003845108.1, YP_001322041.1, ZP_06425397.1, YP_001311673.1, YP_003935519.1, NP_348286.1, ZP_02027123.1, ZP_08532470.1, YP_001664465.1, YP_002950277.1, YP_004820818.1, 30 ZP_07709086.1, ZP_08211979.1, ZP_02211576.1, ZP_05979314.1, ZP_02074622.1, YP_003677577.1, CBK83142.1, YP_003477715.1, ZP_02206646.1, BAD11094.1, ZP_01860365.1, ZP_03226899.1, NP_623752.1, YP_003988617.1, ZP_08005605.1, YP_003599607.1, YP_003831638.1, YP_003564885.1, YP_004587379.1, AEN87678.1, YP_001376086.1, YP_004819378.1, ZP_04152833.1, YP_001126403.1, ZP_03147541.1,

ZP_04218902.1, ZP_08609344.1, ZP_00240356.1, YP_002368967.1, ZP_04147476.1,
 ZP_04176201.1, ZP_04269443.1, YP_003666354.1, ZP_04073820.1, ZP_04103879.1,
 NP_833876.1, ZP_04285820.1, ZP_04187800.1, ZP_04313571.1, ZP_03231885.1,
 ZP_03237173.1, ZP_04086212.1, ZP_04302360.1, ZP_08094177.1, NP_980529.1,
 5 ZP_04098303.1, YP_085496.1, ZP_04170515.1, YP_002447739.1, BAD11089.1,
 ZP_00394509.1, YP_001646798.1, YP_002315321.1, NP_846616.1, ZP_04066826.1,
 YP_896508.1, YP_003866727.1, ZP_00741048.1, YP_001487375.1, ZP_06875892.1,
 ZP_04291055.1

10 Everything in this application relating to the sequence data from data bank codes from the prior art comes from the NCBI (National Center for Biotechnology Information, access date: 19.10.2011) data bank, specifically using the release available online on 19.10.2011.

15 Alternatively, isobutyryl-CoA may be obtained from isobutyric acid using isobutyryl-coenzyme A synthetase or ligase. In a preferred embodiment, the term "isobutyryl-coenzyme A ligase", as used here, is understood to mean an enzyme that catalyses the conversion of isobutyric acid to isobutyryl-CoA using coenzyme A and nucleoside triphosphate. In a particularly preferred embodiment, the term "isobutyryl-coenzyme A synthetase", as used here, is understood to mean an isobutyryl-coenzyme A ligase, wherein the NTP hydrolysed in the course of the
 20 reaction is ATP. Those skilled in the art can find suitable enzymes in the prior art, for example: NP_579516.1, NP_125992.1, YP_004423263.1, YP_004070968.1, YP_182878.1, YP_002306709.1, YP_002959654.1, YP_004762301.1, YP_002581616.1, YP_002994502.1, YP_004623157.1, NP_143577.1, YP_002307387.1, NP_579566.1, YP_004623106.1,
 25 YP_004763660.1, YP_002583149.1, YP_002959108.1, YP_002993622.1, YP_001736558.1, YP_003649375.1, YP_004423314.1, ZP_04874839.1, YP_183356.1, ZP_04874991.1, YP_001041242.1, YP_003860266.1, NP_126044.1, NP_143628.1, YP_003669211.1, YP_002428622.1, YP_001013511.1, YP_004175933.1, YP_004174284.1, YP_001012369.1, YP_004781520.1, YP_004071372.1, NP_769799.1, YP_429257.1, CAJ70793.1,
 30 ZP_08257475.1, YP_930006.1, NP_618478.1, ZP_08667208.1, YP_001239140.1, YP_004438172.1, YP_003400029.1, YP_001206872.1, NP_070039.1, YP_003727548.1, YP_004625200.1, ZP_08422040.1, YP_460839.1, ZP_08631067.1, ZP_02883796.1, YP_002953381.1, ZP_08110577.1, YP_003542795.1, ZP_08905433.1, ZP_06908198.1, YP_001581540.1, NP_632517.1, YP_004519194.1, YP_004515899.1, YP_004120624.1,

ZP_07293826.1, CAJ73927.1, ZP_07331643.1, YP_001278815.1, ZP_08840735.1,
 YP_002289530.1, YP_001637486.1, YP_004342727.1, ZP_07026137.1, ZP_08112481.1,
 YP_003487360.1, YP_001540910.1, ZP_07946223.1, YP_685524.1, YP_004812635.1,
 ZP_08677213.1, ZP_08803651.1, ADI05837.1, YP_874976.1, YP_002465105.1,
 5 YP_003355503.1, ZP_07026765.1, YP_001430231.1, YP_004893707.1, YP_003766745.1,
 YP_004627663.1, YP_003649567.1, ZP_07307686.1, YP_001546514.1, YP_686303.1,
 YP_002992636.1, YP_004516207.1, YP_001154008.1, YP_004338243.1, YP_003357973.1

10 Lastly, isobutyryl-CoA may be prepared from isobutyric acid by means of isobutyrate-coenzyme
 A transferase. In a preferred embodiment, the term "isobutyrate-coenzyme A transferase", as
 used here, is an enzyme that catalyses the formation of isobutyryl-CoA from isobutyric acid by
 transferring coenzyme A from an acyl-CoA functioning as donor. Those skilled in the art can find
 suitable enzymes in the prior art, for example: NP_149326.1, AAB53234.1, YP_001310904.1,
 15 AAD54947.1, AAP42564.1, CAQ57984.1, YP_001886322.1, NP_622378.1, ZP_08693244.1,
 ZP_07926619.1, ZP_08555875.1, ZP_04390377.1, ZP_01867058.1, ZP_04573915.1,
 ZP_07913714.1, ZP_07923474.1, ZP_08691337.1, ZP_08600063.1, ZP_02692961.1,
 ZP_08582386.1, ZP_00144733.1, ZP_05815087.1, ZP_06524353.1, ZP_07952599.1,
 YP_004254308.1, YP_003039857.1, YP_003828410.1, ZP_06175535.1, NP_602657.1,
 20 ZP_06748826.1, ZP_06749807.1, ZP_04970682.1, ADO77683.1, AAO18070.1,
 ZP_05887867.1, AEJ99145.1, EGB63075.1, NP_931005.1, YP_003968227.1, ZP_08327315.1,
 ZP_06025832.1, YP_003260518.1, YP_003016746.1, YP_001452140.1, EGW68380.1,
 ZP_02424926.1, ZP_03828051.1, EGB72667.1, EFW53769.1, ZP_03001766.1,
 ZP_05402063.1, YP_049390.1, ZP_08690265.1, YP_003936148.1, YP_002382110.1,
 25 NP_416725.1, YP_003941041.1, YP_001744415.1, YP_003296165.1, ZP_07151665.1,
 NP_754650.1, YP_002413271.1, EGC06740.1, YP_001459023.1, ZP_05272741.1,
 ZP_04005084.1, YP_541501.1, YP_002335226.1, YP_001089188.1, ZP_04054428.1,
 YP_001784143.1, YP_001306376.1, ZP_07820010.1, ZP_03065638.1, YP_004441693.1,
 NP_905281.1, YP_001321984.1, ZP_06636026.1, YP_003296060.1, ZP_07903700.1,
 30 YP_004509865.1, ZP_08626421.1, YP_002933615.1, YP_002771575.1, ZP_06715088.1,
 ZP_01548307.1, ZP_06982396.1, ZP_08643079.1, YP_002497558.1, YP_001513889.1,
 NP_438933.1, YP_248482.1, YP_531878.1, YP_002746872.1, YP_002744076.1,
 ZP_01792337.1, YP_002940319.1, YP_001471175.1, ZP_01220381.1,
 YP_002123783.1, NP_149327.1, CAQ57985.1, YP_001886321.1, AAD54948.1,

YP_001310905.1, AAP42565.1, ZP_05092257.1, NP_622379.1, ZP_08555876.1,
 ZP_02692960.1, YP_002335225.1, YP_001306375.1, ZP_08693245.1, YP_001513888.1,
 YP_001321983.1, ZP_07926620.1, ZP_02424916.1, YP_001409735.1, ZP_06983458.1,
 YP_003828409.1, YP_004707898.1, YP_003936149.1, ZP_07577382.1, YP_001089189.1,
 5 YP_001471174.1, ZP_05272742.1, YP_002940318.1, ZP_05402064.1, YP_004254317.1,
 YP_003968226.1, CBK81879.1, ZP_07819217.1, YP_001740168.1, YP_049389.1,
 ZP_08709179.1, YP_001918401.1, YP_003016745.1, NP_905290.1, YP_004509856.1,
 ZP_03828050.1, YP_426559.1, YP_001929287.1, YP_001568118.1, ZP_04390271.1,
 ZP_07913715.1, ZP_07820042.1, YP_003260519.1, ZP_08691338.1, ZP_01548308.1,
 10 ZP_08327314.1, ZP_04970681.1, ZP_04054413.1, ZP_08690266.1, ZP_05887868.1,
 ZP_06748825.1, YP_001918068.1, ZP_08731713.1, NP_602656.1, ZP_06524354.1,
 ZP_01867057.1, ZP_04573916.1, ZP_05815086.1, ZP_06025831.1, ZP_00144734.1,
 ZP_08600062.1, YP_001784144.1, EGQ80092.1, ZP_06175534.1, ADO77682.1,
 ZP_01220382.1, YP_597732.1, YP_003945474.1, YP_004219013.1, YP_002562694.1,
 15 YP_001788168.1, YP_002285170.1, NP_268527.1, YP_001392125.1, CBZ04738.1,
 ZP_06921170.1, ZP_07461446.1, YP_531879.1, YP_002805353.1, YP_003452384.1,
 YP_001255346.1, YP_001385091.1, YP_878775.1, EGC06741.1, NP_663914.1,
 YP_059486.1, YP_002382109.1, YP_001884900.1, ZP_07307813.1, ZP_02621896.1,
 ZP_07903699.1, ZP_08729700.1, YP_001309762.1, YP_001768507.1, YP_602949.1,
 20 EGL48602.1, XP_501388.1, XP_002841479.1, XP_002481641.1, XP_002147496.1,
 XP_001879757.1, XP_661332.1, XP_003295652.1, XP_001936644.1, AAK40365.1,
 XP_001802255.1, XP_002383405.1, XP_001390976.1, XP_001212457.1, EGP83670.1,
 XP_001227675.1, XP_003176313.1, XP_001268294.1, XP_751117.1, EGF82407.1,
 XP_001258382.1, EFW13413.1, XP_003065510.1, EGD93452.1, EEH22314.1,
 25 XP_001247983.1, EGE09225.1, XP_003022194.1, CBX98353.1, XP_003014185.1,
 XP_002564448.1, XP_003239146.1, EGX51025.1, EGO01287.1, XP_002792936.1,
 EFQ30503.1, XP_001838038.1, XP_002847737.1, EGO55093.1, XP_957979.1,
 XP_001547410.1, EGR48848.1, XP_003038014.1, EER44122.1, EFY99528.1, EGC42434.1,
 EEH09119.1, EFY92418.1, EGS22244.1, XP_002629107.1, XP_002548743.1,
 30 XP_001904655.1, EFX03923.1, XP_716276.1, XP_002422356.1, XP_388121.1,
 XP_001586993.1, EGX96527.1, XP_368380.1, NP_595848.1, XP_003345762.1, XP_759662.1,
 XP_003001963.1, EGG06029.1, XP_002175297.1, XP_001386078.2, XP_003040746.1,
 XP_459426.2, EDK36000.2, CBQ73919.1, EGU85384.1, XP_001525161.1, XP_001731221.1,
 XP_002490853.1, XP_001486721.1

The next step in the biotechnological synthesis of 3-hydroxyisobutyric acid according to the invention comprises bringing the product from step b), the isobutyryl-CoA, into contact with an isobutyryl-coenzyme A dehydrogenase. In a preferred embodiment, the term "isobutyryl-coenzyme A dehydrogenase", as used here, is understood to mean an enzyme that catalyses the oxidation of isobutyryl-coenzyme A to methacrylyl-coenzyme A with release of reduction equivalents. Suitable examples include the polypeptides known from the prior art with the databank codes XP_501919.2, EDP50227.1, XP_001267173.1, XP_751977.1, EFW17827.1, XP_001241675.1, XP_003070631.1, XP_002376988.1, EGS22147.1, XP_001271742.1, XP_002794645.1, XP_001214528.1, XP_959931.1, EGO55678.1, EEH46977.1, XP_002543210.1, XP_001401697.1, EEH07104.1, BAE59223.1, EGU83504.1, XP_002627767.1, XP_002483661.1, EFX03379.1, XP_003048205.1, EGX54111.1, XP_002150528.1, EFQ35634.1, XP_001548029.1, XP_659303.1, XP_002841387.1, XP_001791413.1, XP_001904778.1, XP_390966.1, XP_003015640.1, EGD94205.1, XP_003233609.1, XP_003018507.1, XP_002561081.1, XP_360875.1, EFY92504.1, XP_003344493.1, CBX95087.1, EGC41158.1, EGX92432.1, XP_003169516.1, EFZ00003.1, EGR49157.1, EGP87134.1, XP_002849756.1, XP_003302688.1, XP_001937377.1, EEH18077.1, XP_001227538.1, XP_001586947.1, AAK63186.1, XP_001538624.1, AAQ04622.1, EGF84480.1, EER45206.1, XP_502873.1, EGS21840.1, XP_752854.1, XP_003170973.1, CBF88712.1, XP_001264273.1, XP_003232243.1, EGD97329.1, XP_002479178.1, XP_658428.1, XP_002844533.1, EGE05996.1, XP_001223344.1, EGX95352.1, XP_001389698.2, CAK37343.1, EGR51332.1, XP_003068884.1, XP_002146883.1, XP_001243830.1, CAP65331.1, XP_001268770.1, XP_001818195.1, EFQ34732.1, XP_001210950.1, XP_962250.1, EEH50726.1, XP_001804465.1, XP_003023750.1, EGO58886.1, CBX97678.1, XP_002561648.1, EEH15844.1, XP_389837.1, XP_363106.2, EFY97392.1, EFY90016.1, EGU81915.1, XP_002621381.1, EEQ89840.1, EGX53945.1, XP_003295397.1, XP_003011911.1, EER38173.1, XP_002792725.1, XP_003045885.1, XP_001935173.1, EGP88451.1, XP_001584930.1, XP_001836878.1, EGG04035.1, XP_003005525.1, XP_001553916.1, XP_762332.1, CBQ71452.1, EFX05387.1, XP_568632.1, XP_001884381.1, EGO01481.1, XP_003332014.1, XP_003197572.1, XP_001731213.1, XP_003026264.1, EGF80206.1, XP_003346492.1, XP_003324899.1, EEH09831.1, XP_002582344.1, EGT41105.1, XP_002640134.1, CBJ32167.1, XP_002607968.1, EFW43327.1, XP_003099748.1, CAF95757.1, NP_491859.1, XP_002471089.1, YP_001611803.1, XP_002904727.1, EGG17601.1, EFX71478.1,

CBN81547.1, XP_002640162.1, ADY46184.1, XP_003099703.1, EFA76871.1, AAH82665.1, 2JIF_A, XP_001658431.1, CAD38535.2, AAH13756.1, NP_001124722.1, NP_001600.1, XP_003255101.1, XP_003283361.1, CAJ81939.1, XP_002640145.1, NP_491871.1, XP_001104844.1, AAH54428.1

5

The next step of the method according to the invention comprises the hydration of methacrylyl-coenzyme A to form 3-hydroxyisobutyryl-coenzyme A by means of a methacrylyl-coenzyme A hydratase. In a preferred embodiment, the term "methacrylyl-coenzyme A hydratase", as used here, is understood to mean an enzyme that catalyses the addition of a water molecule onto methacrylyl-coenzyme A to form 3-hydroxyisobutyric acid. Examples include the polypeptides known from the prior art with the databank codes XP_502475.1, XP_003067220.1, XP_001239658.1, XP_002567879.1, XP_002145078.1, XP_001259415.1, CAK97202.1, XP_001211164.1, XP_001401252.2, XP_753374.1, XP_664448.1, CBF71576.1, XP_001274572.1, XP_002340305.1, XP_002845201.1, XP_001824127.1, XP_002795848.1, XP_003304302.1, EGC44435.1, EER38804.1, EEH09966.1, XP_001936195.1, EEH50797.1, EEH15784.1, EGO61149.1, XP_003170409.1, XP_961123.1, EGS18121.1, XP_001554659.1, XP_003230996.1, EGE07573.1, XP_002621253.1, EGE81015.1, EEQ89969.1, XP_361538.2, XP_001224889.1, XP_002381216.1, CBX96718.1, EFY95366.1, XP_001595164.1, XP_001911969.1, EGX51365.1, EFY87978.1, EFQ29854.1, EGU81865.1, XP_003050469.1, XP_003352189.1, XP_002839588.1, XP_003002061.1, EGD96635.1, XP_003022976.1, XP_003010670.1, EFX03685.1, EGR47862.1, XP_002584325.1, XP_387195.1, EGX94938.1, XP_002616791.1, XP_462069.2, XP_001800531.1

Finally, the hydrolysis of the product from step d), the 3-hydroxyisobutyryl-CoA, is required to release the desired product, 3-hydroxyisobutyric acid. For this purpose, the possibility exists initially to subject the product to extreme pH conditions by addition of acid or base, which promote the hydrolysis without the action of a further enzyme. In a particularly preferred embodiment, the hydrolysis takes place however by bringing the product from step c) into contact with a 3-hydroxyisobutyryl-coenzyme A hydrolase. In a preferred embodiment, the term "3-hydroxyisobutyryl-coenzyme A hydrolase", as used here, is understood to mean an enzyme which hydrolyses 3-hydroxyisobutyryl-coenzyme A to 3-hydroxyisobutyric acid and coenzyme A. The following proteins may be cited here as examples: XP_504911.1, XP_003066853.1, XP_001246264.1, XP_385460.1, EFY92465.1, XP_363761.1, XP_003346508.1, EFY97405.1,

EEQ90955.1, XP_002623105.1, XP_001223375.1, XP_002794385.1, XP_003046454.1,
 EGO58901.1, EEH47368.1, EGS21819.1, EEH18429.1, AAK07843.1, XP_002540650.1,
 XP_002484211.1, XP_002150057.1, EFQ36202.1, EDP49675.1, XP_750988.1,
 XP_003235672.1, EGR51338.1, XP_003013762.1, XP_003019423.1, EGE05569.1,
 5 XP_003169276.1, EGD98503.1, EEH06901.1, XP_001544047.1, EGC47721.1,
 XP_001821058.1, EGE82172.1, XP_002842837.1, XP_002835633.1, EGX53716.1,
 EFX05960.1, XP_001590627.1, XP_001552254.1, XP_962266.2, EGX95378.1,
 XP_001392906.1, XP_003302932.1, CBF89164.1, EGU77782.1, EGP84417.1,
 XP_001258223.1, XP_001268201.1, XP_002569077.1, XP_001214240.1, EER38573.1,
 10 ADD19825.1, XP_001939164.1, XP_658197.1, XP_001248657.1, XP_315590.3,
 XP_003047713.1, EFR21351.1, EGP83804.1, EFX82586.1, EFN83706.1, XP_001799030.1,
 XP_002423077.1, XP_002073789.1, XP_001987737.1, XP_002050275.1, XP_002091863.1,
 XP_002005175.1, XP_001974736.1, EGF81169.1, EFW47689.1, XP_002149358.1,
 XP_002149354.1, CBY01415.1, NP_611373.1, CAP65353.1, XP_002569208.1, AAL39202.2,
 15 XP_002543763.1, XP_001664110.1, XP_002034506.1, XP_002565243.1, XP_003049329.1,
 XP_001360407.1, XP_001865614.1

Biologically active enzymes are used, according to the invention, in steps b) to d). In this
 20 connection, as long as at least one of the enzymes is used in the form of a cell which, compared
 to its wildtype, has a reduced activity of a 3-hydroxyisobutyric acid dehydrogenase or a variant
 thereof, as in the case of all enzymatically active polypeptides used according to the invention,
 these may be cells comprising enzymatically active polypeptides or their lysates or preparations
 of the polypeptides at all purification levels, from the intact cell or its crude lysate up to the pure
 25 polypeptide, which have the respective biologically active enzyme in endogenous or
 recombinant form, preferably overexpressed. In this field, numerous methods are known to
 those skilled in the art with which enzymatically active polypeptides can be overexpressed in
 suitable cells and purified or isolated. All expression systems available to those skilled in the art
 can thus be used for the expression of the polypeptides, for example, vectors of the pET type or
 30 pGEX type. Chromatographic methods are suitable for purification, for example affinity
 chromatography purification of a recombinant protein provided with a for example tag by using
 an immobilised ligand, for example, a nickel ion in the case of a histidine tag, of immobilised
 glutathione in the case of a glutathione S-transferase fused onto the target protein or of
 immobilised maltose in the case of a tag containing maltose-binding protein. Those skilled in the

art are also aware how they can work out suitable reaction conditions in the context of their routine experimentation, under which the enzyme of interest shows activity, preferably optimal activity. These conditions include, for example, the selection of suitable buffers, the evaluation and adjustment of the optimal pH, a specific salt concentration and specific minimum protein concentration; see, for example, Cornish-Bowden, 1995.

If purified enzymes are used for the method according to the invention and not intact living cells, then the former may be used either in soluble form or immobilised. Suitable methods are known to those skilled in the art by which polypeptides may be covalently or non-covalently immobilised on organic or inorganic solid phases, for example by sulphydryl-coupling chemistry (e.g. kits from the Pierce company).

Since the method according to the invention however makes use of a plurality of enzymes with different cofactors, which possibly are added in stoichiometric amounts in the case of purified polypeptides, the enzymes required for the method are provided, in a particularly preferred embodiment, in the form of a single whole-cell catalyst, i.e. in the form of a viable, metabolically active cell. The enzymes may be presented on the surface of the whole-cell catalyst, as described in the prior art, for example in DE 60216245. However, it is very particularly preferred that the enzymes dependent on regenerating cofactors, more preferably all enzymes, are localised in such a way that their active centres remain in contact with the interior of the cell, so that the required cofactors and cosubstrates are acquired from the cell metabolism and further resupplied.

The preparation of mutants of a cell which has a specific enzymatic activity, with the aim of reducing this enzymatic activity for the mutants to be obtained compared to the wildtype of the cell, is feasible to those skilled in the art using standard methods in the field of molecular biology, genetics and microbiology (Sambrook *et al.*, 1989). For example, a random mutagenesis by treatment of wildtype cells with radioactive radiation followed by a step for selecting suitable mutants by determining the enzymatic activity of isolated colonies using suitable assays is possible, as described for numerous enzymes in the prior art (Cornish-Bowden, 1995). Further methods comprising the insertion of a deactivating point mutations, for example into the promoter or into the active centre of the enzymatically active polypeptide, is a method also established for decades (Fersht and Winter, 2008).

In a preferred embodiment, the cell used is a prokaryotic, preferably a bacterial, cell. In a further preferred embodiment, it is a mammalian cell. In a further preferred embodiment, it is a lower eukaryotic cell, preferably a yeast cell. Examples of prokaryotic cells include *Escherichia*, particularly *Escherichia coli*, and strains of the genus *Pseudomonas* and *Corynebacterium*.

5 Examples of lower eukaryotic cells include the genera *Saccharomyces*, *Candida*, *Pichia*, *Yarrowia*, *Schizosaccharomyces*, particularly the strains *Candida tropicalis*, *Schizosaccharomyces pombe*, *Pichia pastoris*, *Yarrowia lipolytica* and *Saccharomyces cerevisiae*. In the most preferred embodiment, it is *Yarrowia lipolytica*.

10 An aspect essential to the teaching according to the invention consists in the fact that a cell is used whose 3-hydroxyisobutyric acid dehydrogenase activity, or the activity of a variant thereof, is reduced. In a preferred embodiment, the term "3-hydroxyisobutyric acid dehydrogenase activity", as used here, is understood to mean the activity of an enzyme that oxidises 3-hydroxyisobutyric acid to the aldehyde. In a preferred embodiment, the 3-hydroxyisobutyric acid

15 dehydrogenase is an enzyme from the group which comprises the polypeptides known from the prior art XP_504911.1, XP_003066853.1, XP_001246264.1, XP_385460.1, EFY92465.1, XP_363761.1, XP_003346508.1, EFY97405.1, EEQ90955.1, XP_002623105.1, XP_001223375.1, XP_002794385.1, XP_003046454.1, EGO58901.1, EEH47368.1, EGS21819.1, EEH18429.1, AAK07843.1, XP_002540650.1, XP_002484211.1,

20 XP_002150057.1, EFQ36202.1, EDP49675.1, XP_750988.1, XP_003235672.1, EGR51338.1, XP_003013762.1, XP_003019423.1, EGE05569.1, XP_003169276.1, EGD98503.1, EEH06901.1, XP_001544047.1, EGC47721.1, XP_001821058.1, EGE82172.1, XP_002842837.1, XP_002835633.1, EFX05960.1, XP_001590627.1, XP_001552254.1, XP_962266.2, XP_001392906.1, XP_003302932.1, CBF89164.1, EGP84417.1,

25 XP_001258223.1, XP_001268201.1, XP_002569077.1, XP_001214240.1, EER38573.1, XP_001939164.1, XP_658197.1, XP_001248657.1, XP_003047713.1, EGP83804.1, XP_001799030.1, EGF81169.1, XP_002149358.1, XP_002149354.1, CBY01415.1, CAP65353.1, XP_002569208.1, XP_002543763.1, XP_002565243.1, XP_003049329.1, XP_001933034.1, XP_002551090.1, XP_001209304.1, XP_001796105.1, XP_003305815.1,

30 CBY01417.1, XP_002144318.1, XP_003035025.1, XP_003047232.1, EDK39415.2, XP_003070936.1, XP_001878640.1, XP_001833463.1, XP_001484132.1, XP_003051032.1, XP_719244.1, XP_001796108.1, XP_456589.2, XP_001384410.2, XP_002421055.1, XP_719127.1, XP_001524095.1, XP_003336106.1, EGN96107.1, XP_003043164.1, XP_001903154.1, XP_758336.1, XP_003051445.1, CBX93804.1, XP_002614534.1,

EFW22385.1, XP_003047715.1, XP_003009661.1, XP_001903159.1, XP_002144320.1, XP_754672.2, EGG05569.1, more preferably is an enzyme from the group XP_504911.1, XP_003066853.1, XP_001246264.1, XP_385460.1, EFY92465.1, XP_363761.1, XP_003346508.1, EFY97405.1, EEQ90955.1, XP_002623105.1, XP_001223375.1, 5 XP_002794385.1, XP_003046454.1, EGO58901.1, EEH47368.1, EGS21819.1, EEH18429.1, AAK07843.1, XP_002540650.1, XP_002484211.1, XP_002150057.1, EFQ36202.1, EDP49675.1, XP_750988.1, XP_003235672.1, EGR51338.1, XP_003013762.1, XP_003019423.1, EGE05569.1, XP_003169276.1, EGD98503.1, EEH06901.1, XP_001544047.1, EGC47721.1, XP_001821058.1, EGE82172.1, XP_002842837.1, 10 XP_002835633.1, EFX05960.1, XP_001590627.1, XP_001552254.1, XP_962266.2, XP_001392906.1, XP_003302932.1, CBF89164.1, EGP84417.1, XP_001258223.1, XP_001268201.1, XP_002569077.1, XP_001214240.1, EER38573.1, XP_001939164.1, XP_658197.1, XP_001248657.1, XP_003047713.1, XP_002551090.1, EDK39415.2, XP_001484132.1, XP_719244.1, XP_456589.2, XP_001384410.2, XP_002421055.1, 15 XP_719127.1, XP_001524095.1, XP_002614534.1, XP_504911.1, particularly preferably is XP_504911.1 XP_002551090.1, EDK39415.2, XP_001484132.1, XP_719244.1, XP_456589.2, XP_001384410.2, XP_002421055.1, XP_719127.1, XP_001524095.1, XP_002614534.1, and most preferably is XP_504911.1.

20 In a preferred embodiment, the 3-hydroxyisobutyric acid dehydrogenase is a 3-hydroxyisobutyric acid dehydrogenase from the group which comprises the polypeptides known from the prior art BAC82381.1, NP_746775.1, YP_004703920.1, YP_001670886.1, ADR61938.1, YP_001269834.1, YP_001747642.1, YP_606441.1, BAJ07617.1, YP_257885.1, EGH62730.1, ZP_06461142.1, ZP_05642104.1, YP_004351842.1, EGH86869.1, 25 YP_002874705.1, EGH24275.1, ZP_07777517.1, ZP_07003462.1, ZP_07264531.1, EGH72043.1, YP_233798.1, EGH66664.1, EGH33025.1, EGH77479.1, EGH54475.1, EFW86611.1, EGH13085.1, ZP_03399204.1, NP_790630.1, YP_346429.1, ZP_04590292.1, EGH46911.1, YP_004681354.1, YP_840711.1, YP_002007768.1, YP_298456.1, ZP_06495709.1, YP_001777122.1, YP_837675.1, YP_624179.1, YP_001117046.1, 30 YP_555519.1, YP_004360017.1, ZP_07673810.1, YP_004714189.1, YP_003607711.1, YP_557465.1, YP_001810630.1, YP_003749513.1, ZP_08140457.1, AEA83842.1, YP_001861262.1, YP_001892508.1, ZP_03264187.1, ADY83615.1, YP_001844789.1, YP_002233766.1, ZP_02893156.1, ZP_06693498.1, YP_001705868.1, YP_001715485.1, YP_775329.1, ADX90568.1, ZP_06059137.1, ADX01770.1, ZP_05825497.1, ZP_06069662.1,

YP_372791.1, YP_002254778.1, AEG71628.1, YP_001584514.1, ZP_02358230.1,
 ZP_03569839.1, YP_439994.1, ZP_02365286.1, YP_554218.1, YP_004473140.1,
 YP_001889364.1, ZP_03585594.1, YP_110641.1, YP_003734018.1, ZP_06839562.1,
 YP_001583635.1, ZP_00944342.1, ZP_03573494.1, YP_001115788.1, ZP_03582471.1,
 5 YP_776268.1, YP_623275.1, ZP_04522920.1, ZP_04947734.1, ZP_02910304.1,
 YP_371475.1, YP_001811564.1, YP_002798276.1, YP_003910785.1, YP_004230293.1,
 ZP_02881368.1, ZP_03822695.1, ZP_02891780.1, ZP_06726280.1, CBJ40252.1,
 ZP_02376988.1, ZP_05359923.1, YP_002908300.1, YP_004348870.1, YP_001172440.1,
 YP_003747923.1, YP_046276.1, NP_522210.1, YP_001156335.1, ZP_03268101.1,
 10 ZP_07236476.1, YP_001861075.1, ZP_05136769.1, YP_293155.1, YP_001083192.1,
 YP_001970187.1, YP_002026611.1, YP_003776462.1, ZP_02381313.1, ADP96674.1,
 EGF41785.1, ZP_08410855.1, ZP_05911432.1, AEL06416.1, ZP_01989307.1,
 ZP_06178628.1, NP_636638.1, ZP_01260019.1, ZP_04929809.1, ZP_08460617.1,
 YP_004068587.1, YP_002553266.1, ZP_06877402.1, YP_002439068.1, NP_800628.1,
 15 ZP_08100296.1, NP_252259.1, YP_001279202.1, ZP_01367000.1, YP_001346959.1,
 ZP_01133887.1, EGM15746.1, YP_339977.1, ZP_04921053.1, ZP_04764368.1, NP_762450.2,
 YP_986257.1, YP_789596.1, YP_004191179.1, YP_004416219.1, NP_937094.1,
 YP_002794225.1, ZP_02244049.1, ZP_05943914.1, YP_450771.1, YP_200485.1,
 ZP_08178115.1, NP_717293.1, ZP_06730192.1, ZP_04958952.1, ZP_03698449.1,
 20 ZP_04922804.1, YP_003288698.1, YP_001141739.1, ZP_08188278.1, YP_786279.1,
 ZP_05127790.1, YP_363098.1, ZP_01104144.1, ZP_05886382.1, ZP_05620602.1,
 ZP_01614260.1, NP_641651.1, ZP_06705559.1, ZP_01260775.1, ZP_06182137.1,
 ZP_05879122.1, YP_001631119.1, ZP_08552251.1, ZP_08570660.1, ZP_01738211.1,
 ZP_01893199.1, ZP_08520681.1, ZP_08182597.1, YP_264191.1, YP_001414164.1,
 25 ZP_08638362.1, YP_422950.1, EGF41343.1, ZP_00056040.1, ZP_08700476.1, NP_800135.1,
 ZP_08272093.1, ZP_08181910.1, ZP_02194300.1, ZP_03698989.1, YP_004235082.1,
 preferably is an enzyme from the group comprising the enzymes BAC82381.1, NP_746775.1,
 YP_004703920.1, YP_001670886.1, ADR61938.1, YP_001269834.1, YP_001747642.1,
 YP_606441.1, BAJ07617.1, YP_257885.1, EGH62730.1, ZP_06461142.1, ZP_05642104.1,
 30 YP_004351842.1, EGH86869.1, YP_002874705.1, EGH24275.1, ZP_07777517.1,
 ZP_07003462.1, ZP_07264531.1, EGH72043.1, YP_233798.1, EGH66664.1, EGH33025.1,
 EGH77479.1, EGH54475.1, EFW86611.1, EGH13085.1, ZP_03399204.1, NP_790630.1,
 YP_346429.1, ZP_04590292.1, EGH46911.1, ZP_06495709.1, YP_004714189.1,
 ZP_08140457.1, AEA83842.1, ADY83615.1, YP_001844789.1, ZP_06693498.1,

YP_001705868.1, YP_001715485.1, ADX90568.1, ZP_06059137.1, ADX01770.1, ZP_05825497.1, ZP_06069662.1, YP_004473140.1, YP_003734018.1, YP_002798276.1, ZP_03822695.1, ZP_06726280.1, ZP_05359923.1, YP_001172440.1, YP_046276.1, ZP_07236476.1, YP_001083192.1, ZP_04929809.1, ZP_08460617.1, ZP_06877402.1, 5 YP_002439068.1, NP_252259.1, YP_001279202.1, ZP_01367000.1, YP_001346959.1, EGM15746.1, YP_789596.1, ZP_05620602.1, YP_264191.1, YP_580776.1, YP_792542.1, YP_004379211.1, ZP_06880384.1, YP_001186868.1, ZP_04932430.1, ZP_01364121.1, YP_002442182.1, NP_249434.1, YP_001350119.1, EGH98403.1, 3OBB_A, 3Q3C_A. In a preferred embodiment, the phrase "a cell which, compared to its wildtype, has a reduced activity of a 3-hydroxyisobutyric acid dehydrogenase or a variant thereof" means that it is a cell which is 10 genetically modified compared to its wildtype in such a way that the activity of a 3-hydroxyisobutyric acid dehydrogenase, or a variant, for this cell compared to the activity of the identical 3-hydroxyisobutyric acid dehydrogenase or of the corresponding variant for the wildtype of the cell is reduced, preferably by at least 10, 20, 30, 50, 75, 90, 95 or 99 %. In a particularly preferred embodiment, the activity of the enzyme for the genetically modified cell is 15 no longer detectable. In a further particularly preferred embodiment, the genetic modification causing the reduction in activity refers exclusively to the activity of a specific 3-hydroxyisobutyric acid dehydrogenase of the cell, in contrast to the possibility that several non-specific enzymatic activities of the cell are reduced, for example through a defect in the folding mechanisms of the cell, which might cause numerous enzymatic activities of the cell to be defective. A comparison 20 of the enzymatic activities of the genetically modified cell and its wildtype takes place under identical conditions and using standard assays for the determination of a dehydrogenase activity. The dehydrogenase activity can be monitored, for example, in a continuous spectrophotometric assay, when the enzyme, in pure form or in the form of a cell lysate, is 25 incubated with substrate, i.e. 3-hydroxyisobutyric acid and redox factor and the reaction progress is monitored by means of the absorbance of the redox factor.

Different conditions are possible when carrying out the method according to the invention. The temperature may be more than 20 °C, 30 °C, 40, 50, 60, 70 °C or more than 80 °C, preferably 30 up to 100 °C, provided that, in the case of the use of a living cell and of a suitable enzyme preparation, the selected cell and the selected enzymes are viable and show activity. It is known to those skilled in the art which organisms are viable at which temperatures, for example from text books such as Fuchs/Schlegel, 2007. In the case of a living yeast cell, the temperature can be 5 to 45 °C, preferably 15 to 42 °C, more preferably 20 to 30 °C. In the case of a Gram-

negative bacterium, preferably a bacterium from the Enterobacteriaceae family, most preferably *E. coli*, the temperature can be 5 to 45 °C, preferably 15 to 42 °C, more preferably 20 to 30 °C, most preferably 35 to 40 °C.

- 5 For culturing the cell according to the invention, numerous culture media are possible, for example, in the case of using a yeast cell, YPD, YPN and YNB, which may be supplemented with amino acids, for example with 0.01 g/l tryptophan, or with glucose, for example at a concentration of 1 % (w/v). In the case of the use of a bacterium from the Enterobacteriaceae family, preferably *E. coli*, culturing is possible in complete media such as LB medium or high cell
10 density medium (HCD medium) consisting of NH_4SO_4 1.76 g, K_2HPO_4 19.08 g, KH_2PO_4 12.5 g, yeast extract 6.66 g, Na_3 citrate 1.96 g, NH_4Fe citrate (1 %) 17 ml, US3 trace element solution 5 ml, feed solution (glucose 50 % w/v, $\text{MgSO}_4 \cdot 7 \text{H}_2\text{O}$ 0.5 % w/v, NH_4Cl 2.2 % w/v) 30 ml per litre.

- In a preferred embodiment, cells used in the method according to the invention are used in
15 another medium to the one used for steps a) to d) of the method. In a particularly preferred embodiment, the medium used for the culture is a complete medium and the medium used for steps a) to d) is a minimal medium. The method according to the invention, if it is conducted using viable cells, is conducted, after culture of the cells, preferably in transformation buffer containing per litre $(\text{NH}_4)_2\text{H}_2\text{PO}_4$ 8 g, NaCl 0.5 g, $\text{MgSO}_4 \cdot 7 \text{H}_2\text{O}$ 0.48 g, US3 trace element solution
20 15 ml. 1 litre of the US 3 trace element solution is composed of HCl 37 % 36.5 g, $\text{MnCl}_2 \cdot 4\text{H}_2\text{O}$ 1.91 g, $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$ 1.87 g, Na EDTA $\cdot 2\text{H}_2\text{O}$ 0.8 g, H_3BO_3 0.3 g, $\text{Na}_2\text{MoO}_4 \cdot 2\text{H}_2\text{O}$ 0.25 g, $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$ 4.7 g, $\text{FeSO}_4 \cdot 7 \text{H}_2\text{O}$ 17.8 g, $\text{CuCl}_2 \cdot 2\text{H}_2\text{O}$ 0.15 g and its pH is adjusted to 5.4.

- The concentration of isobutyric acid at the start of the reaction, if this is provided as ready-to-
25 use reactant at the beginning of the method, is 0.01 to 2, preferably 0.05 to 1, most preferably 0.1 to 0.2 % (w/v). If 3-hydroxyisobutyric acid is prepared using glucose as the carbon source, which is metabolised to suitable precursors by a competent strain, its concentration in the medium at the start is 1 % (w/v).

- 30 The steps a) to d) of the method according to the invention are preferably conducted at atmospheric pressure. When preparing isobutyric acid from isobutane, it can be advantageous to conduct the alkane hydroxylase reaction in the presence of relatively high pressures, in the presence of a gas mixture comprising, preferably comprising predominantly, isobutane. In a

preferred embodiment, the pressure is more than 1.5, 2, 3 or 4 bar. In a further embodiment, the pressure is 0.5 to 4, preferably 1 to 3, most preferably 1 to 1.5 bar.

In a most preferred embodiment of the present invention, the object of the invention is achieved wherein a cell of the genus *Yarrowia*, preferably *Yarrowia lipolytica*, for which the activity of the hydroxyisobutyric acid dehydrogenase Yali0F02607g, or a variant thereof, is reduced by deletion compared to the activity of the corresponding wildtype cell, is brought into contact with isobutyric acid in aqueous solution.

The present invention is further illustrated by the following figures and non-limiting examples, from which further characteristics, embodiments, aspects and advantages of the present invention may be inferred.

Fig. 1 shows a particularly preferred sequence according to the invention of enzymatically catalysed reactions comprising the conversion of isobutyric acid to isobutyryl-CoA by isobutyrate kinase and phosphotransisobutyrylase or isobutyryl-coenzyme A synthetase/ligase or isobutyrate-coenzyme A transferase in step b), the oxidation of isobutyryl-coenzyme A to methacrylyl-coenzyme A by isobutyryl-coenzyme A dehydrogenase in step c), the addition of water onto methacrylyl-coenzyme A with formation of 3-hydroisobutyryl-coenzyme A in step d) and its hydrolysis to 3-hydroxyisobutyric acid in step e).

Examples

Example 1

Preparation of a recombinant *Yarrowia lipolytica* cell with attenuated 3-hydroxyisobutyric acid dehydrogenase activity

1. Construction of the gene disruption cassette GDC-YI02607PT for the deletion of the 3-hydroxyisobutyric acid dehydrogenase gene *YalI0F02607g* Accession Number: XP_504911.1)

For the construction of a *YalI0F02607g* knockout mutant in *Y. Lipolytica*, the promotor and terminator region of the gene *YalI0F02607g* was cloned. Chromosomal DNA from *Y. lipolytica* H222 (*MATa*) served as matrix for the PCR. The gene knockout was conducted in the following strains: *Y. lipolytica* H222-41 (*MATa ura3-41*) and *Y. lipolytica* H222-SW4-2 (*MATa ura3-302 SUC2 ku70Δ-1572 trp1Δ-1199*). The promotor and terminator region of the gene coding for the 3-hydroxyisobutyric acid dehydrogenase (*YalI0F02607g*) was amplified in a PCR by means of the oligonucleotides 3HIBDH-Pfw (SEQ.-ID-No. 01), 3HIBDH-Prv (SEQ.-ID-No. 02) (promoter region), 3HIBDH-Tfw (SEQ.-ID-No. 03) and 3HIBDH-Trv (SEQ.-ID-No. 04) (terminator region) from the chromosomal DNA of *Y. lipolytica* H222. The following parameters were used for the PCR: promoter region, 1 x: initial denaturation, 98 °C, 3 min; 35 x: denaturation, 98 °C, 0:10 min, annealing, 59.5 °C, 0:45 min; elongation, 72 °C, 0:35 min; 1 x: terminal elongation, 72 °C, 5 min. Terminator region, 1 x: initial denaturation, 98 °C, 3 min; 35 x: denaturation, 98 °C, 0:10 min, annealing, 59.5 °C, 0:45 min; elongation, 72 °C, 0:35 min; 1 x: terminal elongation, 72 °C, 5 min. For the amplification, the Phusion™ High-Fidelity Master Mix from New England Biolabs (Frankfurt) was used according to the manufacturer's recommendations. In this manner the promoter fragment was provided with an I-SceI restriction site at the 3'-end and the terminator fragment was provided with an I-SceI restriction site at the 5'-end. For this, the following oligonucleotides were used:

3HIBDH-Pfw:

5'- CAC ACA TCC AGA GCT CTA TG -3' (SEQ.-ID-No. 01)

3HIBDH-Prv:

5'-TAT ATA CTA TAT TAC CCT GTT ATC CCT AGC GTA ACT ACA AAT ACA AGT TTT AAG CTG -3' (SEQ.-ID-No. 02, containing an I-SceI recognition sequence at the 5'-end)

3HIBDH-Tfw:

5'- TAT ATA AGT TAC GCT AGG GAT AAC AGG GTA ATA TAG GCT GTG TAT GTG TTA GGG TG -
3' (SEQ.-ID-No. 03, containing an *I-SceI* recognition sequence at the 5'-end)

3HIBDH-Trv:

5 5'- GGT GAC CTT CAG GTG CAC CA -3' (SEQ.-ID-No. 04)

2. Fusion of the promoter and terminator fragment

The PCR products of the promotor and terminator region (1060 and 970 base pairs respectively) were purified using the "QIAquick PCR-Purification Kits" (Qiagen, Hilden) according to the manufacturer's instructions. In a subsequent *crossover* PCR, the two PCR products were used as matrix and an amplification was conducted with the primers 3HIBDH-Pfw (SEQ.-ID-No. 01) and 3HIBDH-Trv (SEQ.-ID-No. 04). The following parameters were used for the PCR: 1 x: initial denaturation, 98 °C, 3 min; 35 x: denaturation, 98 °C, 0:10 min, annealing, 59.5 °C, 0:45 min; elongation, 72 °C, 1:00 min; 1 x: terminal elongation, 72 °C, 5 min. A 2.071 kilobase pair PCR product (SEQ.-ID-Nr. 05) was formed by the complementarity of the *I-SceI* restriction site. To isolate the DNA from an agarose gel the target DNA was excised from the gel with a scalpel and purified with the "Quick Gel Extraction Kit" (Qiagen, Hilden). This was conducted according to the manufacturer's instructions. In the next step the PCR product was ligated into the pCR-Blunt II-Topo (Zero Blunt TOPO PCR Cloning Kit with One Shot TOP10 Chemically Competent *E. coli*, Invitrogen, Karlsruhe) vector. The resulting pCRBluntIITopo::P_T_3HIBDH_YI plasmid (SEQ.-ID-No. 06) is 5.59 kilobase pairs long. The ligation and the chemically competent *E. Coli* transformation were carried out according to the manufacturer's instructions. The authenticity of the plasmid was checked by a restriction analysis with *EcoRI*, *XhoI* and *PstI*.

3. Construction of the *knockout* mutants *Y. lipolytica* H222-SW-4-2 Δ 3HIBDH and *Y. lipolytica* H222-41

Δ 3HIBDH

For construction of the *knockout* mutant, the integration of a marker gene is required. For this purpose, the 1.3 kilobase pair "loxP-URA3-loxR" DNA fragment, which contains the *URA3* gene, was excised from the pJMP113 (Fickers *et al.*, 2003) vector by means of a *I-SceI* restriction. The "loxP-URA3-loxR" fragment was purified over on an agarose gel using a "Quick Gel Extraction Kit" (Qiagen, Hilden) according to the manufacturer's instructions. The resulting fragment was ligated into the pCRBluntIITopo::P_T_3HIBDH_YI vector (SEQ.-ID-No. 06), cleared with *I-SceI*. The resulting plasmid pCRBluntIITopo::P_T_3HIBDH_YI_ura (SEQ.-ID-No. 07) is 6.899 kilobase pairs in size. The ligation and also the transformation of chemically competent *E. coli* DH5 α cells (New England Biolabs, Frankfurt) was

carried out in a manner known to those skilled in the art. The authenticity of the plasmid was checked by a restriction with *Xma*I, *Sca*I and *Sac*I.

In order to obtain the gene disruption cassette GDC-YI02607PT for the deletion of ORFYal/OF02607g required for the gene *knockout*, the plasmid pCRBluntIIITopo::P_T_3HIBDH_YI_ura (SEQ.-ID-No. 07) was used as matrix for the PCR with the following oligonucleotides and parameters: 3HIBDH-Pfw (SEQ.-ID-No. 01) and 3HIBDH-Trv (SEQ.-ID-No. 04); 1 x: initial denaturation, 98 °C, 3 min; 35 x: denaturation, 98 °C, 0:10 min, annealing, 65 °C, 0:45 min; elongation, 72 °C, 1:45 min; 1 x: terminal elongation, 72 °C, 5 min. The desired 3.38 kilobase pair fragment (SEQ.-ID-No. 8) was purified by means of a "Quick Gel Extraction Kit" (Qiagen, Hilden) on an agarose gel, according to the manufacturer's instructions, checked by the restriction with *Xma*I and *Xmn*I and used for the integrative transformation of *Y. lipolytica* H222-SW4-2 and *Y. lipolytica* H222-41.

The transformation was conducted using the lithium acetate method (Barth G and Gaillardin C (1996) *Yarrowia lipolytica*. In: Wolf, K. (eds) Nonconventional yeasts in biotechnology. Springer, Berlin Heidelberg New York, pp 313-388). The uracil prototrophic transformants obtained were checked by colony PCR. The following parameters were used for the PCR: 1 x: initial denaturation, 98 °C, 3 min; 35 x: denaturation, 98 °C, 0:10 min, annealing, 60 °C, 0:45 min; elongation, 72 °C, 1:30 min; 1 x: terminal elongation, 72 °C, 5 min. For this, the following oligonucleotids were used:

fw-3HIBDH-ah:

5'- GAG TCG CAG ATT CAG GAA AT -3' (SEQ.-ID-No. 09)

rv-3HIBDH-ah:

5'- TCA CCT TCT GAT CAC GGT GT -3' (SEQ.-ID-No. 10)

In the case of a successful disruption of the *Yal/OF02607g* gene coding for the 3-hydroxyisobutyric acid dehydrogenase, a 1.005 kilobase pair fragment should be amplified. In fact, corresponding clones could be identified, which were further processed below.

4. Restoration of the uracil auxotrophy

The restoration of the uracil auxotrophy in the uracil prototrophic transformants was carried out according to Fickers *et al.*, 2003. Initially, competent cells were produced. For this, the transformants were cultured in 5 ml of YPD pH 4 (10 g/l yeast extract, 10 g/l peptone, 10.5 g/l citric acid, 2 % (w/v) glucose and 0.5 M

sodium citrate to adjust the pH) for 8 h at 30 °C and 190 rpm in 100 ml baffled flasks . After 8 h this pre-culture was used to inoculate 10 ml of YPD medium pH 4 in 250 ml baffled flasks with an optical density (OD₆₀₀) of 0.05. All flasks were incubated at 30 °C and 190 rpm. On the following day these pre-cultures were harvested (500 g, 5 min, RT) on reaching a cell count between $9 \cdot 10^7$ and $1.5 \cdot 10^7$ per ml (counting using a Neubauer chamber), washed twice in 10 ml of TE buffer (10 mM Tris-HCl, 1 mM Na EDTA, pH 8), subsequently diluted in 30 ml of 0.1 % (w/v) lithium acetate and incubated for 1 h at 28 °C and 60 rpm. Subsequently the cells were again centrifuged (500 g, 5 min, RT), resuspended in 3 mL of 0.1 % (w/v) lithium acetate, aliquoted in 100 µl portions and used immediately. All further steps were conducted on ice.

For the transformation of the pUB4Cre plasmid (Fickers *et al.*, 2003), 100 µl of the competent cells were mixed with 200 – 800 ng plasmid DNA and 2.5 µL of boiled salmon sperm DNA (10 mg/ml) (Invitrogen, Karlsruhe). After addition of 0.7 mL of 40 % PEG4000 (w/v; dissolved in 0.1 M lithium acetate, pH 6) the cells were incubated for 1 h at 28 °C with shaking. Heat shock at 39 °C followed for 10 min in a water bath. To the cells were added 1.2 mL of 0.1 % (w/v) lithium acetate and 2 x 250 µl were very carefully applied to YPD plates with 500 µg/ml hygromycin.

After incubation for 3 to 10 days at 30 °C, the clones obtained were checked phenotypically on agar plates with YNB medium (6.7 g/l DifcoTM yeast nitrogen base w/o amino acids) and glucose with or without uracil. In order to remove the pUB4Cre plasmid from the cell, the transformants were incubated in 10 ml of YPD medium in several 100 ml baffled flasks at 30 °C and 190 rpm for 24 h and streaked on YPD plates. The resulting clones were checked phenotypically on agar plates and by PCR (as described in section 3).

In this manner the following strains were constructed:

- H222-SW4-2 Δ 3HIBDH
- H222-41 Δ 3HIBDH

Example 2

Production of 3-hydroxyisobutyric acid with glucose as the sole carbon source by means of genetically modified *Y. lipolytica* cells, in which the 3-hydroxyisobutyric acid dehydrogenase activity has been attenuated

5

The *Y. lipolytica* H222-41 Δ 3HIBDH strain constructed in example 1, alongside the corresponding wildtype H222-41, were cultured in 10 mL of YNB medium (6.7 g/l Difco™ yeast nitrogen base w/o amino acids) containing 0.2 g/l uracil, 0.01 g/l tryptophan and 5 % (w/v) glucose overnight at 28 °C and 190 rpm. The following morning, these pre-cultures were each used to inoculate 20 mL of YNB medium containing 0.2 g/l uracil, 0.01 g/l tryptophan and 1 % (w/v) glucose in 100 ml baffled flasks with an optical density (OD₆₀₀) of 0.5. All flasks were incubated at 28 °C and 190 rpm.

10

After a time period of 70 h, 1 g/l of ammonium sulphate was added and after 95 h the concentrations of 3-hydroxyisobutyric acid in the mixtures were analysed by IC. For the chromatographic separation in the ICS-2000 RFIC (Dionex, Corporation, Sunnyvale, USA) a RFICTM TonPac column (2 × 250 mm, column temperature 30 °C, + precolumn AG15 4 × 50 mm, flow rate 0.38 ml/min) was used.

15

The strains reached an OD₆₀₀ of ca. 30. Whereas the control strain *Y. lipolytica* H222-41 did not produce any 3-hydroxyisobutyric acid, in the case of the *Y. lipolytica* H222-41 Δ 3HIBDH derived from it, the formation of 4.5 mg/l 3-hydroxyisobutyric acid could be detected.

20

Example 3

Production of 3-hydroxyisobutyric acid starting from isobutyric acid with genetically modified *Y. lipolytica* cells, in which the 3-hydroxyisobutyric acid dehydrogenase activity has been attenuated

5

The *Y. lipolytica* strains H222-SW-4-2 Δ 3HIBDH and H222-41 Δ 3HIBDH constructed in example 1 were cultivated, alongside an unmodified control strain (H222-SW-4-2), in 10 mL of YNB medium (6.7 g/l Difco™ yeast nitrogen base w/o amino acids) containing 0.01 g/l tryptophan and 1 % (w/v) glucose at 30 °C and 190 rpm overnight. The following morning these precultures were each used to inoculate 20 mL of YNB medium containing 0.2 g/l uracil, 0.01 g/l tryptophan, 1 % (w/v) glucose and 0.2 % (w/v) isobutyric acid (titrated with NaOH, pH: 5.1; after 24 h 0.2 % isobutyric acid was freshly added) in 100 ml baffled flasks with an optical density (OD₆₀₀) of 0.5. All flasks were incubated at 30 °C and 190 rpm. The H222-SW4-2-strains reached an OD₆₀₀ of 2-3 whereas the H222-41 strains grew to an OD₆₀₀ of ca. 10.

10

At 24 h and 48 h time points the concentrations of 3-hydroxyisobutyric acid in all mixtures were analysed by IC. (see Fig. 1). The culture supernatant was diluted with ddH₂O 1:10, such that the measured values were in the calibration range. For the chromatographic separation in the ICS-2000 RFIC (Dionex, Corporation, Sunnyvale, USA) a RFICTM TonPac column (2 × 250 mm, column temperature 30 °C, + precolumn AG15 4 × 50 mm, flow rate 0.38 ml/min) was used.

20

After 24 h all the *Y. lipolytica* strains reached the stationary growth phase. The pH for the H222-41 strains declined during the growth to 3.3 to 3.7, while a pH of 2 was detected for the H222-SW-4-2 strains. After 24 h and 48 h the modified *Y. lipolytica* strains H222-SW-4-2 Δ 3HIBDH and H222-41 Δ 3HIBDH Δ 3HIBDH and H222-41 Δ 3HIBDH reached a higher yield than the respective unmodified strains H222-SW-4-2 and H222-41. *Y. lipolytica* H222-41 Δ 3HIBDH converts over 90 % isobutyric acid to 3-hydroxyisobutyric acid after 24 h and over 80 % after 48 h.

25

By deletion of *Yal0F02607g* in *Y. lipolytica* H222-41 and H222-SW-4-2 the yield of 3-hydroxyisobutyric acid production from isobutyric acid could be considerably increased (see Fig. 1).

30

Example 4

Production of 3-hydroxybutyric acid (3-HIB) from glucose or isobutyric acid (IBA) as the sole carbon source by *Y. lipolytica* H222 (wildtype, WT) and genetically modified *Y. lipolytica* H222 Δ 3HIBDH (ura)-8 with attenuated 3-hydroxyisobutyric acid dehydrogenase activity (Δ).

5

a) Biomass production on a shaking flask scale

10

Cryocultures of *Y. lipolytica* H222 Δ 3HIBDH (ura)-8 (in the following denoted as Δ) and *Y. lipolytica* H222 (in the following denoted as wildtype (WT)) were autoclaved on YPD agar plates per litre prepared from yeast extract 10g, peptone 20g, agar agar 12g, and complemented with separately autoclaved glucose 10g, plated out and incubated for 24h at 28°C.

15

Per strain, 2 1000 ml shake flasks with baffles were charged with 100 ml of YPD medium (above medium without agar agar, each with 3 drops of Delamex antifoam), inoculated in each case with 2 full inoculation loops from the agar plates and incubated for 20h at 30°C and 180rpm (amplitude 2.5cm) (residual glucose 0g/l, OD $\geq$ 20).

Tab.1

Strain	pH	OD	Glucose[g/l]
Δ	7.06	20.9	0.029
WT	7.47	23.7	0.015

20

The cultures were then placed under sterile conditions in 50ml falcon tubes and centrifuged at 5000rpm. The pellets were washed 4x with 0.9% saline. Then, 2 pellets of each strain were resuspended in 50 ml of transformation buffer and combined.

25

The transformation buffer was composed per sterile-filtered litre of (NH₄)H₂PO₄ 8g, NaCl 0.5g, MgSO₄ x 7 H₂O 0.48 g, trace element solution US3 15 ml. 1 litre of the US3 trace element solution US 3 was composed of HCl 37% 36.5g, MnCl₂ x 4H₂O 1.91g, ZnSO₄ x 7H₂O 1.87g, Na EDTA x 2H₂O 0.8g, H₃BO₃ 0.3g, Na₂MoO₄ x 2H₂O 0.25g, CaCl₂ x 2H₂O 4.7g, FeSO₄ x 7 H₂O 17.8g, CuCl₂ x 2H₂O 0.15g. This solution was separately sterile-filtered and added to the buffer under sterile conditions. The pH of the buffer was adjusted to 5.4.

30

b) Biotransformation

To each of 4 1000 ml shaking flasks with baffles were added, under sterile conditions, 50 ml of the said transformation buffer pH 5.4, each with 3 drops of Delamex antifoam. For each strain, 0.2% (w/v) isobutyric acid was added, under sterile conditions, to one shaking flask to a final volume of 100ml, and 1% (w/v) glucose was added to a second shaking flask. One shaking flask with IBA and one with glucose were each inoculated with 50 ml of resuspended pellet of *Y. lipolytica* H222 from a). The *Y. lipolytica* H222 Δ 3HIBDH (ura)-8 was likewise processed. The initial OD was ca. 14. The shaking flasks were incubated at 30°C and 180rpm. The sampling was carried out after 0.6 and 24 hours. Microscopic controls revealed no lysed cells in any culture over the entire time. The glucose was measured with a YSI measuring device supplied by the Kreienbaum company, the isobutyric acid and 3-hydroxyisobutyric acid was measured by HPLC using an Aminex column and the OD was measured with a Spectralphotometer at 600nm.

Results:

Tab. 2

OD

t [h]	WT IBA	WT Glc	Δ IBA	Δ Glc
0	13.8	13.6	15.0	13.6
6	13.5	19.2	12.8	25.3
24	13.3	18.2	10.6	16.4

The glucose was partly metabolised to the structure of biomass. With IBA as the sole carbon source, no biomass production took place.

Tab. 3

Substrate concentration of IBA / Glucose [mg/l]

Strain	WT IBA		WT Glucose		Δ IBA		Δ Glucose	
t [h]	IBA	Glucose	IBA	Glucose	IBA	Glucose	IBA	Glucose
0	1914	20	0	8450	1808	10	0	8520
6	676	0	0	3240	1267	0	0	1770
24	0	0	0	0	422	0	0	0

Both substrates were metabolised both by *Y. lipolytica* H222, and by *Y. lipolytica* H222 Δ 3HIBDH (ura)-8.

Tab.4

Concentration of 3-HIB [mg/l]

t [h]	WT IBA	WT Glucose	Δ IBA	Δ Glucose
0	1	1	10	5
6	50	0	821	21
24	0	0	2042	52

5 In the case of *Y. lipolytica* H222, only with IBA could 3-HIB be briefly detected as a metabolic product.

10 With *Y. lipolytica* H222 Δ 3HIBDH (ura)-8 and glucose as substrate, low amounts of free 3-HIB could be detected. Of the IBA used, 15.7 mmol/l were consumed. From this, 18.6 mmol/l can theoretically be formed. 19.6 mmol/l were measured. The IBA consumed is therefore completely converted to 3-HIB.

Example 5

Production of 3-hydroxyisobutyric acid starting from ketoisovalerate with genetically modified *Y. lipolytica* cells, in which the 3-hydroxyisobutyric acid dehydrogenase activity has been attenuated

5

The *Y. lipolytica* strain H222-41 Δ 3HIBDH constructed in example 1, alongside the corresponding wildtype *Y. lipolytica* H222-41, was cultured in 10 mL of YNB medium (6.7 g/l Difco™ yeast nitrogen base w/o amino acids) containing 0.2 g/l uracil, 0.01 g/l tryptophan and 1 % (w/v) glucose overnight at 30 °C and 190 rpm. On the following day, these pre-cultures were each used to inoculate 25 mL of YNB
10 medium containing 0.2 g/l uracil, 0.01 g/l tryptophan, 6 % (w/v) glucose and 0.65% (w/v) ketoisovalerate (after 25.5 h 0.5% (w/v) ketoisovalerate was freshly added to the culture and 0.3% (w/v) ketoisovalerate was added after 49.5 h) in 100 ml baffle flasks with an optical density (OD₆₀₀) of 0.5. All flasks were incubated at 30 °C and 190 rpm.

15 Over the course of time, the optical density (OD₆₀₀) was determined and the 3-hydroxyisobutyric acid content was analysed by IC in all mixtures. During the culture period, sufficient glucose and ketoisovalerate was at all times present in the medium. After ca. 24 h, all *Y. lipolytica* strains reached the stationary growth phase. During the growth, the pH dropped to ca. 3.

20 By deletion of *Yal0F02607g* in *Y. lipolytica* H222-41 the 3-hydroxyisobutyric acid production from ketoisovalerate could be increased from 2g/l of 3-hydroxyisobutyric acid to more than 5g/l of 3-hydroxyisobutyric acid (see Fig. 2).

Example 6

Production of 3-hydroxyisobutyric acid by a 2 step process, starting from isobutane, using a genetically modified *E. coli* W3110 with the monooxygenase (alkBGT) from *P. putida* GPO1, to give isobutyric acid, which is further converted by genetically modified *Y. lipolytica* H222 (ura)-8, in which the 3-hydroxyisobutyric acid dehydrogenase activity has been attenuated, with IBA as the sole carbon source.

Step 1

Production of isobutyric acid from isobutane by *E. coli* W3110 with the monooxygenase (alkBGT) from *P. putida* GPO1.

a) Production of biomass on a 10l scale

Pre-seeding culture: 1 litre of LB Medium with 50µl of kanamycin was prepared from a solution of yeast extract 5g, peptone 10g, NaCl 0.5g and 50µl of kanamycin. The pH was adjusted to 7.4 with 5% NH₄OH. The solution is autoclaved for 20 minutes at 121°C.

5 x 25ml of this solution were placed in 100 ml shake flasks with baffles and each was inoculated with 200µl of a glycerol cryoculture of *E. coli* W3110 pBT10 (DE10200710060705). These cultures were incubated for 18 hours at 37°C and 180rpm (amplitude 2.5cm).

Seeding culture: 1 litre of high cell density medium (HCD medium) consisting of NH₄SO₄ 1.76g, K₂HPO₄ 19.08g, KH₂PO₄ 12.5g, yeast extract 6.66g, Na₃ citrate 1.96g, NH₄FE citrate (1%) 17ml, US3 trace element solution 5ml, feed solution (glucose 50% w/v, MgSO₄ x 7 H₂O 0.5% w/v, NH₄Cl 2.2% w/v) 30ml, and also 50 µg kanamycin was made up with demineralised water. 1 litre of the US 3 trace element solution comprised HCl 37% 36.5g, MnCl₂ x 4H₂O 1.91g, ZnSO₄ x 7H₂O 1.87g, Na EDTA x 2H₂O 0.8g, H₃BO₃ 0.3g, Na₂MoO₄ x 2H₂O 0.25g, CaCl₂ x 2H₂O 4.7g, FeSO₄ x 7 H₂O 17.8g, CuCl₂ x 2H₂O 0.15g. 948ml of solution with NH₄SO₄ to Na₃-citrate are autoclaved, the remainder were in each case separately sterile filtered and subsequently added under sterile conditions. The pH was 6.8.

5 x 75 ml of the HCD medium in 1000 ml shake flasks with baffles were each inoculated with 25 ml of pre-seed culture and cultured for 30h at 37°C and 180rpm (amplitude 2.5cm).

Induction culture: Each 25 ml of the culture broth were used as inoculum for 75 ml of modified M9 medium (sterile filtered) with the following composition per litre: 15 g glucose, 6.79 g Na_2PO_4 , 3 g KH_2PO_4 , 0.5 g NaCl, 2 g NH_4Cl , 15 g yeast extract, 0.49 g $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$, 1 ml trace element solution (as in the seed culture) and 50 μg kanamycin in 1000 ml shake flasks. The cultures are

5

A sterile 10 l fermenter was charged with 7 l of a sterile medium with the composition (per litre) $(\text{NH}_4)_2\text{SO}_4$ 1.75 g, $\text{K}_2\text{HPO}_4 \times 3 \text{H}_2\text{O}$ 19 g, KH_2PO_4 12.5g, yeast extract 6.6 g, $\text{Na}_3\text{citrate} \times 2\text{H}_2\text{O}$ 2.24 g, glucose 15 g, $\text{MgSO}_4 \times 7 \text{H}_2\text{O}$ 0.49 g, $\text{NH}_4\text{Fe citrate}$ (1% w/v) 16.6ml, trace element solution (as in the seed culture) 15ml and kanamycin 50 μg and 2 ml of Delamex antifoam. As

10

feed, an autoclaved solution of glucose (50% w/v) with $\text{MgSO}_4 \times 7\text{H}_2\text{O}$ 10g/l was connected, for the purposes of pH correction with 0.5M H_2SO_4 and 25% NH_4OH .

The cultures from the shaking flasks were combined under sterile conditions and, by means of a

15

transfer bottle, inoculated into the fermenter. The fermentation conditions were adjusted to: pO_2 30%, airflow 6nlpm, stirrer 400 – 1200rpm, temperature 37°C, pH7, feed start 8 h, feed rate 150 – 250 g/h. After 19 h the temperature was lowered to 30°C, the feed was stopped and the culture

20

b) Biotransformation of isobutane to isobutyric acid

25

The pellets from 200 ml of culture were resuspended in 10 ml of conversion buffer. The conversion buffer consisted of 70 mM $(\text{NH}_4)_2\text{H}_2\text{PO}_4$ buffer, pH 7 containing per litre 8g $(\text{NH}_4)_2\text{H}_2\text{PO}_4$, 0.5 g NaCl, 0.49 g $\text{MgSO}_4 \times 7\text{H}_2\text{O}$, 1 ml TE and 50 μg kanamycin. The pH adjustment here was carried out with 5 % NH_4OH .

30

150 ml of buffer with ca. 3 drops of autoclaved antifoam (Delamex) were placed in a 300 ml fermenter. The fermenter was flushed with a gas mixture from a gas cylinder to an initial pressure of 5 bar with 25 % isobutane and 75 % synthetic air by means of a metal sinter perlator with a pore size of 0.2 μm with a flow rate of 12.5 l/h (stp). The fermenter was maintained at 35°C in a

water bath and stirred at 900rpm by means of a magnetic stirrer. The waste air was discharged through a wash bottle filled with 150 ml water.

The fermenter was inoculated via a sampling tube with 30 ml of a pellet produced in a) and resuspended in buffer. The reaction was initiated by the start of a glucose feed (or in the case of iso also glucose batch or by initial charge + feed....) of 1.5 g/lh. After 4.5 hours, a concentration of isobutyric acid of > 350mg/l was reached (3.97mmol/kg).

The pH was adjusted to 5.4 with 1M H₂SO₄ and the gassing was readjusted to compressed air with a flow rate of 12.5 l/h (stp), and the temperature lowered to 30 degrees. (alternatively):

- From each of the fermenters 50 ml of transfer buffer were removed under sterile conditions by canulae and syringes for resuspending the *Yarrowia* cultures (see step 2a)
- the culture was harvested and the biomass was separated off by centrifugation at 8000rpm with 500ml in 1000ml centrifuge tubes, and the supernatant was stored at -20°C until required for transformation with the *Yarrowia* cultures.

Step 2

Production of 3-hydroxyisobutyric acid from isobutyric acid from step 1 by genetically modified *Y. lipolytica* H222 Δ3HIBDH (ura)-8 compared to the wildtype *Y. lipolytica* H222.

a) Production of biomass on a shake flask scale (or alternatively also in the fermenter)

Cryocultures of *Y. lipolytica* H222 Δ3HIBDH (ura)-8 and *Y. lipolytica* H222 were autoclaved on YPD agar plates per litre prepared from yeast extract 10g, peptone 20g, agar agar 12g, and complemented with separately autoclaved glucose 10g, plated out and incubated for 24h at 28°C. Per strain, 2 1000 ml shake flasks with baffles were charged with 100 ml of YPD medium (above medium without agar agar, each with 3 drops of Delamex antifoam), inoculated in each case with 2 full inoculation loops from the agar plates and incubated for 20h at 30°C and 180rpm (amplitude 2.5cm) (residual glucose 0g/l, OD ≥20).

The cultures were then discharged under sterile conditions into 50ml falcon tubes and centrifuged at 5000rpm. The pellets were washed 4x with 0.9% saline. Then, 2 pellets of each strain were resuspended in 50 ml of transformation buffer - fresh or thawed (from step 1b) and combined.

b) Biotransformation of isobutyric acid to 3-hydroxyisobutyric acid

Each of the 50ml of the resuspended pellets of *Y. lipolytica* H222 Δ 3HIBDH (ura)-8 and *Y. lipolytica* H222 were inoculated in a 300ml fermenter with the transformation buffer from step 1b) and stirred for 24h at pH 5.4, 30°C and 900rpm and gassed with 1.2vvm compressed air.

5

After 24 hours, no isobutyric acid and no 3-hydroxyisobutyric acid could be detected in the supernatant for the wildtype *Y. lipolytica* H222. After 24 h, in the case of *Y. lipolytica* H222 Δ 3HIBDH (ura)-8, isobutyric acid could no longer be detected in the supernatant. With regard to 3-hydroxyisobutyric acid, concentrations were of > 413 mg/l, corresponding to the isobutyric acid values of > 3.97 mmol measured at the end of step 1b).

10

Bibliography:

A. Cornish-Bowden (1995), Fundamentals of Enzyme Kinetics, Portland Press Limited, 1995

5 DE 60216245 (2007): FUNCTIONAL DISPLAY OF POLYPEPTIDES

DE10200710060705 (2007): ω -Aminocarbonsäuren oder ihre Lactame, herstellende, rekombinante Zellen (Recombinant cells producing ω -aminocarboxylic acids or their lactams).

10 Sambrook/Fritsch/Maniatis (1989): Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, 2nd edition

William Bauer, Jr. "Methacrylic Acid and Derivatives" in Ullmann's Encyclopedia of Industrial Chemistry 2002, Wiley-VCH, Weinheim

15

Hasegawa et al. (1981), J. Ferment. Technol. 59, pp 203-208

Hasegawa (1981b), Agric. Biol. Chem. 45, pp 2899-2901.

20 Hasegawa et al. (1982), J. Ferment. Technol. 60, pp 501-508

WO 2007/141208: MICROBIOLOGICAL PRODUCTION OF 3-HYDROXYISOBUTYRIC ACID

WO 2008/119738: ENZYME FOR THE PRODUCTION OF METHYLMALONYL COENZYME A
25 OR ETHYLMALONYL COENZYME A, AND USE THEREOF

Patel RN et al. (1983), Journal of Applied Biochemistry 5 (1 - 2), 107 – 120

Barth G and Gaillardin C (1996) *Yarrowia lipolytica*. In: Wolf, K. (eds) Nonconventional yeasts in
30 biotechnology. Springer, Berlin Heidelberg New York, pp 313-388

Van Beilen et al. (2002): Functional Analysis of Alkane Hydroxylases from Gram-Negative and Gram-Positive Bacteria", Journal of Bacteriology, 2002, 184 (6), pp. 1733-1742).

35 Fersht A R and Winter G (2008): Redesigning Enzymes by Site-Directed Mutagenesis, Ciba Foundation Symposium 111 - Enzymes in Organic Synthesis

Fuchs/Schlegel (2007) Allgemeine Mikrobiologie (General Microbiology), 2008, Georg Thieme Verlag

William Bauer, Jr. "Methacrylic Acid and Derivatives" in Ullmann's Encyclopedia of Industrial Chemistry 2002, Wiley-VCH, Weinheim

Claims

1. Method comprising the following steps:

5

a) providing isobutyric acid,

b) bringing isobutyric acid into contact with

10

the combination of isobutyrate kinase and phosphotransisobutyrylase and/or

isobutyryl-coenzyme A synthetase/ligase and/or

isobutyrate-coenzyme A transferase,

15

c) bringing the product from step b) into contact with isobutyryl-coenzyme A dehydrogenase,

d) bringing the product from step c) into contact with methacrylyl-coenzyme A hydratase,
20 and

e) hydrolyzing the product from step d) to form 3-hydroxyisobutyric acid,

25

wherein at least one of the enzymes used in the steps b), c) and d) from the group comprising isobutyrate kinase, phosphotransisobutyrylase, isobutyryl-coenzyme A synthetase/ligase and isobutyrate-coenzyme A transferase, preferably all, is provided in the form of a cell, which, compared to its wildtype, has a reduced activity of a 3-hydroxyisobutyric acid dehydrogenase or a variant thereof.

2. Method according to Claim 1, wherein the isobutyric acid is formed by bringing isobutane into contact with a monooxygenase, preferably an alkane hydroxylase, more preferably one of the alk-BGT type or a variant thereof.
3. Method according to any of Claims 1 to 2, wherein the hydrolysis in step d) is achieved by bringing the product from step d) into contact with a 3-hydroxyisobutyryl-coenzyme A hydrolase.
4. Method according to any of Claims 1 to 3, wherein the cell has both the isobutyryl-coenzyme A dehydrogenase in step c) and the methacrylyl-coenzyme A hydratase in step d) and
the combination of isobutyrate kinase and phosphotransisobutyrylase and/or
isobutyryl-coenzyme A synthetase/ligase and/or
isobutyrate-coenzyme A transferase.
5. Method according to any of Claims 1 to 4, wherein the cell additionally has an alkane hydroxylase, preferably one of the alkBGT type or a variant thereof.
6. Method according to any of Claims 1 to 5, wherein the 3-hydroxyisobutyric acid dehydrogenase is XP_504911.1 or a variant thereof.
7. Cell which has at least one enzyme from the group comprising isobutyryl-coenzyme A synthetase/ligase, isobutyrate-coenzyme A transferase, isobutyrate kinase, phosphotransisobutyrylase, isobutyryl-coenzyme A dehydrogenase and methacrylyl-coenzyme A hydratase and, compared to its wildtype, a reduced activity of a 3-hydroxyisobutyric acid dehydrogenase or a variant thereof.
8. Cell according to Claim 7, wherein the cell has, in addition to an isobutyryl-coenzyme A dehydrogenase, and in addition to a methacrylyl-coenzyme A hydratase,
the combination of isobutyrate kinase and phosphotransisobutyrylase and/or

isobutyryl-coenzyme A synthetase/ligase and/or

isobutyrate-coenzyme A transferase,

5 preferably furthermore a 3-hydroxyisobutyryl-coenzyme A hydrolase.

9. Cell according to any of Claims 7 to 8, further comprising an alkane hydroxylase, preferably one of the alkBGT type or a variant thereof.

10 10. Cell according to any of Claims 6 to 8, wherein the 3-hydroxyisobutyric acid dehydrogenase is XP_504911.1 or a variant thereof.

11. Use of the cell according to any of Claims 7 to 10 for preparing 3-hydroxyisobutyric acid.

15 12. Use according to Claim 11, wherein the 3-hydroxyisobutyric acid dehydrogenase is XP_504911.1 or a variant thereof.

13. Method according to any of Claims 1 to 6, cell according to any of Claims 7 to 10 or use according to any of Claims 11 to 12, wherein the cell is a bacterial or lower eukaryotic cell.

20 14. Method according to any of Claims 1 to 5 or 13, cell according to any of Claims 7 to 10 or 13 or use according to any of Claims 11 to 13, wherein it involves a yeast cell from the group of genera which comprises *Yarrowia*, *Candida*, *Saccharomyces*, *Schizosaccharomyces* and *Pichia* and it preferably involves *Yarrowia lipolytica*.

25 15. Reaction mixture comprising the cell according to any of Claims 7 to 10 or 13 to 14 and also isobutane or isobutyric acid.

SEQUENCE LISTING

<110> Evonik Degussa GmbH
 <120> Biotechnological Production Of 3-Hydroxyisobutyric Acid
 <130> 2011DE00275De
 <160> 10
 <170> PatentIn version 3.5
 <210> 1
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Primer
 <400> 1
 cacacatcca gagctctatg 20
 <210> 2
 <211> 54
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Primer
 <400> 2
 atactatatt accctgttat ccctagcgta actacaaata caagttttaa gctg 54
 <210> 3
 <211> 56
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Primer
 <400> 3
 tatataagtt acgctaggga taacagggta atataggctg tgtatgtggt aggggtg 56
 <210> 4
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Primer
 <400> 4
 ggtgaccttc aggtgcacca 20
 <210> 5
 <211> 2071
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> PCR product

<400> 5
cacacatcca gagctctatg aagagatggg tatcaaaccc cccaagggag tcattcttta 60
cggcgctccc ggaaccggaa agacactgct ggccaaggcc gtcgccaacc agacttctgc 120
tacatttttg cgaatcgttg gatccgagct gatccaaaag tacttgggag acggtccccg 180
actgtgtcga cagattttcc agattgccgc agaacacgca ccgtccattg ttttcacga 240
tgagattgac gctattggaa ccaaacgata cgagtcgacg tctggcggag agcgagaggt 300
gcagcggacc atgctggagc ttctgaacca gctggatgga ttcgacgacc gaggagacgt 360
caaggtaatt atggctacaa acaagattga gtcgctggac cctgcactga ttcgacctgg 420
tcgaatcgac cgaaagattc tgtttgagaa tcccgaactcc accaccaagc gaaagattat 480
gggcatccac acctccaaga tgaacctcaa cgacgatgtt gatctcgagg agtttgtgtc 540
ttccaaggat gaactttctg gagccgacat caaggccatg tgcaccgagg caggtctgct 600
tgctctgcga gagagacgaa tgcgggtcac tgctgaggat ttccgaaccg ctaaagagcg 660
ggtcatgaag aacaagggtg aggagaacct tgaggggtctc tacctgtaag catagaagca 720
ttaacgtatg actataataa atacatcaat gaggtggagg ttgacgggga cttcttcgta 780
tacatactaa catctaacat ctacagtaga tcgaataact tgcaacggta catgccgtca 840
tagaaagacg tttggtagaa aatgcctaata agagacaaca cacattccaa tacacagaca 900
gttacaacca gcagccacat tgttatataa atgtttacca agtgagccta accagtgggt 960
gtaagtcata catcatcatt cattatttag tcatgatcca tgaaatgttt atgcaatacg 1020
tttcacagtt cattgggtca gcttaaaact tgtatttggt atataagtta cgctagggat 1080
aacagggtaa tatagtatat agctgtgtat gtgttagggg gggttttggt gtgttgga 1140
ggagtgccag aaaagagatc ggtctagctt tctcctctgg cctgcggctc accccagatt 1200
tgaacttttg gtttgtcggg ctagtctcgg ggcgcgtgtg ggggagatgc atcaataacc 1260
gcataatagt ggtccactg caggtgtttg gaggtggagc tgaaactttt atttcctaata 1320
atcgtattca agctgtctcc aaaggagcat tcatcctcgc aactcctcgg actagctcca 1380
aaaggcattt ttagccgct ctgcgtacag gtaagggatc cccccacat tatccacca 1440
gcattagtct tgcgttatgt acactcaaca gagttcgtcg attgccgccg aagcggacat 1500
cttcgttggg tgagggacca ggcttgtggt atattaattg gagaggaggg ccgagagggt 1560
tggcgagaag ttacaaattg aactaggagt acacatagaa tgatatacct tctacttcta 1620
ctgacggtcg tagtcacaat acgtgcgtgt gcacaatacg tgcgtgtgta catctgagtt 1680
ataacttgca ctgggttgct agtgatgaac ccacagtgtg attatgtcct gccagtgta 1740
caagtacagc actattatgg gtgttgccacc ctatccatct atataccac catgttagcc 1800
ccgtaagtga gattgattcc cttcatgcgc tccacaagta cagtacatag tcatcgcat 1860
gcatattata tacctacagc atgtacagta tgtactgtaa tagtgggaga tcctacagta 1920
tttgtagtgc tttcttggtg gacatgcata ctttgcacca gtgtcgaaaa tatcgtactt 1980
gtacttaacc actttttgta cttttataac gtgcgtcaaa gcctcttaata tgatgacgct 2040

ccagctatta ttggtgcacc tgaaggtcac c

2071

<210> 6

<211> 5590

<212> DNA

<213> Artificial sequence

<220>

<223> Vektor pCRB1untIITopo::P_T_3HIBDH_Y1

<400> 6

cacacatcca gagctctatg aagagatggg tatcaaaccc cccaagggag tcattcttta	60
cggcgctccc ggaaccggaa agacactgct ggccaaggcc gtcgccaacc agacttctgc	120
tacatttttg cgaatcgttg gatccgagct gatccaaaag tacttgggag acggtccccg	180
actgtgtcga cagattttcc agattgccgc agaacacgca ccgtccattg ttttcacga	240
tgagattgac gctattggaa ccaaacgata cgagtcgacg tctggcggag agcgagaggt	300
gcagcggacc atgctggagc ttctgaacca gctggatgga ttcgacgacc gaggagacgt	360
caaggtaatt atggctacaa acaagattga gtcgctggac cctgcactga ttcgacctgg	420
tcgaatcgac cgaaagattc tgtttgagaa tcccgactcc accaccaagc gaaagattat	480
gggcatccac acctccaaga tgaacctcaa cgacgatgtt gatctcgagg agtttgtgtc	540
ttccaaggat gaactttctg gagccgacat caaggccatg tgcaccgagg caggtctgct	600
tgctctgcga gagagacgaa tgcgggtcac tgctgaggat ttccgaaccg ctaaagagcg	660
ggcatgaag aacaagggtg aggagaacct tgagggtctc tacctgtaag catagaagca	720
ttaacgtatg actataataa atacatcaat gaggtggagg ttgacgggga cttcttcgta	780
tacatactaa catctaacat ctacagtaga tcgaataact tgcaacggta catgccgtca	840
tagaaaagacg tttggtagaa aatgcctaata agagacaaca cacattccaa tacacagaca	900
gttacaacca gcagccacat tgttatataa atgtttacca agtgagccta accagtgggt	960
gtaagtcata catcatcatt cattatttag tcatgatcca tgaaatgttt atgcaatacg	1020
tttcacagtt cattgggtca gcttaaaact tgtatttggt atataagtta cgctagggat	1080
aacagggtaa tatagtatat agctgtgtat gtgttagggg gggttttggt gtgttgga	1140
ggagtgccag aaaagagatc ggtctagctt tatcctctgg cctgcggctc accccagatt	1200
tgaacttttg gtttgtcggg ctagtctcgg ggcgctgtg ggggagatgc atcaataacc	1260
gcataatagt ggtcccactg caggtgtttg gaggtggagc tgaaactttt atttccta	1320
atcgtattca agctgtctcc aaaggagcat tcacctctgc aactcctcgg actagctcca	1380
aaaggcattt ttagccgcgt ctgcgtacag gtaagggatc cccccacat tatccacca	1440
gcattagtct tgcgttatgt aactcaaca gagttcgtcg attgccgccg aagcggacat	1500
cttcgttggg tgagggacca ggcttgtggt atattaattg gagaggaggg ccgagagggt	1560
tggcgagaag ttacaaattg aactaggagt acacatagaa tgatatacct tctacttcta	1620
ctgacggtcg tagtcacaat acgtgcgtgt gcacaatacg tgcgtgtgta catctgagtt	1680

ataacttgca	ctgggttgtc	agtgatgaac	ccacagtgtg	attatgtcct	gcccagtgtg	1740
caagtacagc	actattatgg	gtgttgccacc	ctatccatct	atatacccac	catgttagcc	1800
ccgtaagtga	gattgattcc	cttcatgcgc	tccacaagta	cagtacatag	tcacgcgcat	1860
gcatattata	tacctacagc	atgtacagta	tgtactgtaa	tagtgggaga	tcctacagta	1920
tttgtagtgc	tttcttggtg	gacatgcata	ctttgcacca	gtgtcgaaaa	tatcgtactt	1980
gtacttaacc	actttttgta	cttttataac	gtgcgtaaaa	gcctcttaat	tgatgacgct	2040
ccagctatta	ttggtgcacc	tgaaggctac	cagggcgaa	tctgcagata	tccatcacac	2100
tggcggccgc	tcgagcatgc	atctagaggg	cccaattcgc	cctatagtga	gtcgtattac	2160
aattcactgg	ccgtcgtttt	acaacgtcgt	gactgggaaa	accctggcgt	tacccaactt	2220
aatcgccctg	cagcacatcc	ccctttcgc	agctggcgta	atagcgaaga	ggcccgacc	2280
gatcgccctt	cccaacagtt	gcgcagccta	tacgtacggc	agtttaaggt	ttacacctat	2340
aaaagagaga	gccgttatcg	tctgtttgtg	gatgtacaga	gtgatattat	tgacacgccg	2400
gggcgacgga	tggtgatccc	cctggccagt	gcacgtctgc	tgtcagataa	agtctcccgt	2460
gaactttacc	cggtggtgca	tatcggggat	gaaagctggc	gcatgatgac	caccgatatg	2520
gccagtgtgc	cggtctccgt	tatcggggaa	gaagtggctg	atctcagcca	ccgcgaaaat	2580
gacatcaaaa	acgccattaa	cctgatgttc	tggggaatat	aaatgtcagg	catgagatta	2640
tcaaaaagga	tcttcaccta	gatccttttc	acgtagaaa	ccagtcgcga	gaaacgggtg	2700
tgaccccgga	tgaatgtcag	ctactgggct	atctggacaa	gggaaaacgc	aagcgcaaag	2760
agaaagcagg	tagcttgacg	tgggcttaca	tggcgatagc	tagactgggc	ggttttatgg	2820
acagcaagcg	aaccggaatt	gccagctggg	gcgcccctct	gtaagggttg	gaagccctgc	2880
aaagtaaact	ggatggcttt	ctcgccgcca	aggatctgat	ggcgcagggg	atcaagctct	2940
gatcaagaga	caggatgagg	atcgtttcgc	atgattgaac	aagatggatt	gcacgcaggt	3000
tctccggccg	cttgggtgga	gaggctattc	ggctatgact	gggcacaaca	gacaatcggc	3060
tgctctgatg	ccgccgtgtt	ccggctgtca	gcgcaggggc	gcccggttct	ttttgtcaag	3120
accgacctgt	ccggtgcctt	gaatgaactg	caagacgagg	cagcgcggct	atcgtggctg	3180
gccacgacgg	gcgttccttg	cgcagctgtg	ctcgacgttg	tactgaagc	gggaagggac	3240
tggctgctat	tgggcgaagt	gccggggcag	gatctcctgt	catctcacct	tgctcctgcc	3300
gagaaagtat	ccatcatggc	tgatgcaatg	cggcggctgc	atacgcttga	tccggctacc	3360
tgcccattcg	accaccaagc	gaaacatcgc	atcgagcgag	cacgtactcg	gatggaagcc	3420
ggtcttgtcg	atcaggatga	tctggacgaa	gagcatcagg	ggctcgcgcc	agccgaactg	3480
ttcgccaggc	tcaaggcgag	catgcccgc	ggcgaggatc	tcgtcgtgac	ccatggcgat	3540
gcctgcttgc	cgaatatcat	ggtggaaaat	ggccgctttt	ctggattcat	cgactgtggc	3600
cggctgggtg	tggcggaccg	ctatcaggac	atagcgttgg	ctaccctgga	tattgctgaa	3660
gagcttggcg	gcgaatgggc	tgaccgcttc	ctcgtgcttt	acggtatcgc	cgctcccgat	3720

tcgcagcgca tcgccttcta tcgccttctt gacgagttct tctgaattat taacgcttac	3780
aatttcctga tgcggtatth tctccttacg catctgtgcg gtatttcaca ccgcatacag	3840
gtggcacttt tcggggaaat gtgcgcgga cccctatttg tttatttttc taaatacatt	3900
caaatatgta tccgctcatg agacaataac cctgataaat gcttcaataa tagcacgtga	3960
ggagggccac catggccaag ttgaccagtg ccgttccggt gctcaccgcg cgcgacgtcg	4020
ccggagcggg cgagtcttgg accgaccggc tcgggttctc ccgggacttc gtggaggacg	4080
acttcgccgg tgtggtccgg gacgacgtga ccctgttcat cagcgcggtc caggaccagg	4140
tggtgccgga caacaccctg gcctgggtgt ggggtgcgcg cctggacgag ctgtacgccg	4200
agtgttcgga ggtcgtgtcc acgaacttcc gggacgcctc cgggcccggc atgaccgaga	4260
tcggcgagca gccgtggggg cgggagttcg ccctgcgcg cccggccggc aactgctgct	4320
acttcgtggc cgaggagcag gactgacacg tgctaaaact tcatttttaa tttaaaagga	4380
tctaggtgaa gatccttttt gataatctca tgacaaaat cccttaacgt gagttttcgt	4440
tccactgagc gtcagacccc gtagaaaaga tcaaaggatc ttcttgagat cctttttttc	4500
tgcgcgtaat ctgctgcttg caaacaacaa aaccaccgct accagcgggtg gtttgtttgc	4560
cggatcaaga gctaccaact ctttttccga aggtaactgg cttcagcaga gcgcagatac	4620
caaatactgt ctttctagt tagccgtagt taggccacca cttcaagaac tctgtagcac	4680
cgcctacata cctcgtctg ctaatcctgt taccagtggc tgctgccagt ggcgataagt	4740
cgtgtcttac cgggttgga tcaagacgat agttaccgga taaggcgag cggtcgggct	4800
gaacgggggg ttcgtgcaca cagcccagct tggagcgaac gacctacacc gaactgagat	4860
acctacagcg tgagctatga gaaagcgcca cgcttcccga agggagaaaag gcggacaggt	4920
atccggtaa cggcaggggc ggaacaggag agcgacagag ggagcttcca gggggaaacg	4980
cctggatatc ttatagtcct gtcgggtttc gccacctctg acttgagcgt cgatttttgt	5040
gatgctcgtc aggggggagg agcctatgga aaaacgccag caacgcggcc tttttacggt	5100
tcctgggctt ttgctggcct tttgtcaca tgttctttcc tgcgttatcc cctgattctg	5160
tggataaccg tattaccgcc tttgagttag ctgataccgc tcgccgcagc cgaacgaccg	5220
agcgagcgga gtcagttagc gaggaagcgg aagagcgccc aatacgcaaa ccgcctctcc	5280
ccgcgcgttg gccgattcat taatgcagct ggcacgacag gtttcccagc tggaaagcgg	5340
gcagttagcg caacgcaatt aatgtgagtt agctcactca ttaggcaccc caggctttac	5400
actttatgct tccggctcgt atgttgtgtg gaattgtgag cgataaaca tttcacacag	5460
gaaacagcta tgaccatgat tacgccaagc tatttaggtg acactataga atactcaagc	5520
tatgcatcaa gcttggtacc gagctcggat ccactagtaa cggccgcccag tgtgctggaa	5580
ttcgccctta	5590

<210> 7
<211> 6899

<212> DNA
<213> Artificial sequence

<220>
<223> pCRB1untIITopo::P_T_3HIBDH_Y1_ura

<400> 7
cacacatcca gagctctatg aagagatggg tatcaaaccc cccaagggag tcattcttta 60
cggcgctccc ggaaccggaa agacactgct ggccaaggcc gtcgccaacc agacttctgc 120
tacatttttg cgaatcgttg gatccgagct gatccaaaag tacttgggag acggtccccg 180
actgtgtcga cagattttcc agattgccgc agaacacgca ccgtccattg ttttcatcga 240
tgagattgac gctattggaa ccaaacgata cgagtcgacg tctggcggag agcgagaggt 300
gcagcggacc atgctggagc ttctgaacca gctggatgga ttcgacgacc gaggagacgt 360
caaggtaatt atggctacaa acaagattga gtcgctggac cctgcactga ttcgacctgg 420
tcgaatcgac cgaaagattc tgtttgagaa tcccgactcc accaccaagc gaaagattat 480
gggcatccac acctccaaga tgaacctcaa cgacgatgtt gatctcgagg agtttgtgtc 540
ttccaaggat gaactttctg gagccgacat caaggccatg tgcaccgagg caggtctgct 600
tgctctgcga gagagacgaa tgcgggtcac tgctgaggat ttccgaaccg ctaaagagcg 660
ggtcatgaag aacaagggtg aggagaacct tgagggtctc tacctgtaag catagaagca 720
ttaacgtatg actataataa atacatcaat gaggtggagg ttgacgggga cttcttcgta 780
tacatactaa catctaacat ctacagtaga tcgaataact tgcaacggta catgccgtca 840
tagaaagacg tttggtagaa aatgcctaata agagacaaca cacattccaa tacacagaca 900
gttacaacca gcagccacat tgttatataa atgtttacca agtgagccta accagtgggt 960
gtaagtcata catcatcatt cattatttag tcatgatcca tgaaatgttt atgcaatacg 1020
tttcacagtt cattgggtca gcttaaaact tgtatttggt atataagtta cgctagggat 1080
aacagggtaa tcataacttc gtatagcata cattatacga agttattctg aattccgccc 1140
agagagccat tgacgttctt tctaatttgg accgatagcc gtatagtcca gtctatctat 1200
aagttcaact aactcgtaac tattaccata acatatactt cactgcccc aataaggttc 1260
cgataaaaag ttctgcagac taaatttatt tcagtctcct cttcaccacc aaaatgacct 1320
cctacgaagc tcgagctaac gtccacaagt ccgcctttgc cgctcgagtg ctcaagctcg 1380
tggcagccaa gaaaaccaac ctgtgtgctt ctctggatgt taccaccacc aaggagctca 1440
ttgagcttgc cgataaggtc ggaccttatg tgtgcatgat caagacccat atcgacatca 1500
ttgacgactt cacctacgcc ggcaactgtc tccccctcaa ggaacttgct ctttaagcacg 1560
gtttcttctt gttcaggagc agaaagttcg cagatattgg caacactgtc aagcaccagt 1620
accggtgtca ccgaatcgcc gagtgggtccg atatcaccaa cgcccacggg gtacccggaa 1680
ccggaatcat tgctggcctg cgagctggtg ccgaggaaac tgtctctgaa cagaagaagg 1740
aggacgtctc tgactacgag aactcccagt acaaggagtt cctagtcccc tctcccaacg 1800
agaagctggc cagaggtctg ctcatgctgg ccgagctgtc ttgcaagggc tctctggcca 1860

ctggcgagta	ctccaagcag	accattgagc	ttgcccgatc	cgaccccgag	tttgtggttg	1920
gcttcattgc	ccagaaccga	cctaagggcg	actctgagga	ctggcttatt	ctgacccccg	1980
gggtgggtct	tgacgacaag	ggagacgctc	tcggacagca	gtaccgaact	gttgaggatg	2040
tcatgtctac	cggaacggat	atcataattg	tcggccgagg	tctgtacggc	cagaaccgag	2100
atcctattga	ggaggccaag	cgataccaga	aggctggctg	ggaggcttac	cagaagatta	2160
actgttagag	gtagactat	ggatatgtaa	tttaactgtg	tatatagaga	gcgtgcaagt	2220
atggagcgct	gttcagcttg	tatgatggtc	agacgacctg	tctgatcgag	tatgtatggt	2280
actgcacaac	ctgtgtatcc	gcatgggtctg	tccaatgggg	catgttggtg	tgtttctcgg	2340
aattcgtata	acttcgtata	gcaggagtta	tccgaagcga	tatagggata	acagggtaat	2400
atagtatata	gctgtgtatg	tgtaggggtg	ggttttgggtg	tgtaggaaag	gagtgccaga	2460
aaagagatcg	gtctagcttt	atcctctggc	ctgcggctca	ccccagattt	gaactttggg	2520
tttgtcgggc	tagtctcggg	gcgcgtgtgg	gggagatgca	tcaataaccg	cataatagtg	2580
gtcccactgc	agggtgttgg	agggtggagct	gaaactttta	tttcctaata	tcgtattcaa	2640
gctgtctcca	aaggagcatt	catcctcgca	actcctcgga	ctagctccaa	aaggcatttt	2700
tagccgcgtc	tgcgtagagg	taagggatcc	ccccacatt	atccaccag	cattagtctt	2760
gcgttatgta	cactcaacag	agttcgtcga	ttgccgccga	agcggacatc	ttcgttgggt	2820
gagggaccag	gcttgtggta	tattaatttg	agaggagggc	cgagaggggt	ggcgagaagt	2880
tacaaattga	actaggagta	cacatagaat	gatatacctt	ctacttctac	tgacggtcgt	2940
agtcacaata	cgtagcgtgtg	cacaatacgt	gcgtgtgtac	atctgagtta	taacttgcac	3000
tgggttgtca	gtgatgaacc	cacagtgtga	ttatgtcctg	cccagtgtac	aagtacagca	3060
ctattatggg	tggtgcaccc	tatccatcta	tatacccacc	atgttagccc	cgtaagttag	3120
attgattccc	ttcatgcgct	ccacaagtac	agtacatagt	catcggcatg	catattatat	3180
acctacagca	tgtacagtat	gtactgtaat	agtgggagat	cctacagtat	ttgtagtgtt	3240
ttcttgggtg	acatgcatac	tttgcaccag	tgtcgaaaat	atcgtacttg	tacttaacca	3300
ctttttgtac	ttttataacg	tgcgtaaaag	cctcttaatt	gatgacgctc	cagctattat	3360
tgggtgcacct	gaaggtcacc	agggcgaatt	ctgcagatat	ccatcacact	ggcggccgct	3420
cgagcatgca	tctagagggc	ccaattcgcc	ctatagttag	tcgtattaca	attcactggc	3480
cgtagcttta	caacgtcgtg	actgggaaaa	ccctggcggt	acccaactta	atcgccctgc	3540
agcacatccc	cctttcgcca	gctggcgtaa	tagcgaagag	gcccgcaccg	atcgcccttc	3600
ccaacagttg	cgagccctat	acgtacggca	gtttaagggt	tacacctata	aaagagagag	3660
ccgttatcgt	ctgtttgtgg	atgtacagag	tgatattatt	gacacgccgg	ggcgacggat	3720
ggtagatccc	ctggccagtg	cacgtctgct	gtcagataaa	gtctcccgtg	aactttaccc	3780
ggtaggtgcat	atcggggatg	aaagctggcg	catgatgacc	accgatatgg	ccagtgtgcc	3840
ggctctccgtt	atcggggaag	aagtggctga	tctcagccac	cgcgaaaatg	acatcaaaaa	3900

cgccattaac	ctgatgttct	ggggaatata	aatgtcaggc	atgagattat	caaaaaggat	3960
cttcacctag	atccttttca	cgtagaaagc	cagtccgcag	aaacggtgct	gaccccgat	4020
gaatgtcagc	tactgggcta	tctggacaag	ggaaaacgca	agcgcaaaga	gaaagcaggt	4080
agcttgacgt	gggcttacat	ggcgatagct	agactgggcg	gttttatgga	cagcaagcga	4140
accggaattg	ccagctgggg	cgccctctgg	taaggttggg	aagccctgca	aagtaaactg	4200
gatggctttc	tcgccgcca	ggatctgatg	gcgcagggga	tcaagctctg	atcaagagac	4260
aggatgagga	tcgtttcgca	tgattgaaca	agatggattg	cacgcagggt	ctccggccgc	4320
ttgggtggag	aggctattcg	gctatgactg	ggcacaacag	acaatcggct	gctctgatgc	4380
cgccgtgttc	cggctgtcag	cgcaggggcg	cccggttctt	tttgtcaaga	ccgacctgtc	4440
cgggtgccctg	aatgaactgc	aagacgaggc	agcgcggtca	tcgtggctgg	ccacgacggg	4500
cgttccttgc	gcagctgtgc	tcgacgttgt	caactgaagc	ggaagggact	ggctgctatt	4560
gggcgaagtg	ccggggcagg	atctcctgtc	atctcacctt	gctcctgccg	agaaagtatc	4620
catcatggct	gatgcaatgc	ggcggtgcga	tacgcttgat	ccggctacct	gcccattcga	4680
ccaccaagcg	aaacatcgca	tcgagcgagc	acgtactcgg	atggaagccg	gtcttgctga	4740
tcaggatgat	ctggacgaag	agcatcaggg	gctcgcgcca	gccgaactgt	tcgccaggct	4800
caaggcgagc	atgcccgacg	gcgaggatct	cgctcgtgacc	catggcgatg	cctgcttgcc	4860
gaatatcatg	gtggaaaatg	gccgcttttc	tggattcatc	gactgtggcc	ggctgggtgt	4920
ggcggaccgc	tatcaggaca	tagcgttggc	taccctgat	attgctgaag	agcttggcgg	4980
cgaatgggct	gaccgcttcc	tcgtgcttta	cggatatgcc	gctcccgatt	cgacgcgc	5040
cgcttcttat	cgcttcttg	acgagttctt	ctgaattatt	aacgcttaca	atttctgat	5100
gcggtatttt	ctccttacgc	atctgtgcgg	tatttcacac	cgcatacagg	tggcactttt	5160
cggggaaatg	tgcgcggaac	ccctatttgt	ttatttttct	aaatacattc	aaatatgtat	5220
ccgctcatga	gacaataacc	ctgataaatg	cttcaataat	agcacgtgag	gagggccacc	5280
atggccaagt	tgaccagtgc	cgttccgggtg	ctcaccgcgc	gcgacgtcgc	cggagcggtc	5340
gagttctgga	ccgaccggct	cgggttctcc	cgggacttcg	tggaggacga	cttcgccgggt	5400
gtggtccggg	acgacgtgac	cctgttcatc	agcgcggtcc	aggaccagggt	ggtgccggac	5460
aacaccctgg	cctgggtgtg	ggtgcgcggc	ctggacgagc	tgtacgccga	gtggtcggag	5520
gtcgtgtcca	cgaacttccg	ggacgcctcc	gggccggcca	tgaccgagat	cggcgagcag	5580
ccgtgggggc	gggagttcgc	cctgcgcgac	ccggccggca	actgcgtgca	cttcgtggcc	5640
gaggagcagg	actgacacgt	gctaaaactt	catttttaat	ttaaaaggat	ctagggtgaag	5700
atcctttttg	ataatctcat	gacaaaaatc	ccttaacgtg	agttttcggt	ccactgagcg	5760
tcagaccccg	tagaaaagat	caaaggatct	tcttgagatc	ctttttttct	gcgcgtaatc	5820
tgctgcttgc	aaacaaaaaa	accaccgcta	ccagcggtgg	tttgtttgcc	ggatcaagag	5880
ctaccaactc	tttttccgaa	ggtaactggc	ttcagcagag	cgagataacc	aaatactgtc	5940

cttctagtgt agccgtagtt aggccaccac ttcaagaact ctgtagcacc gcctacatac	6000
ctcgctctgc taatcctgtt accagtggct gctgccagtg gcgataagtc gtgtcttacc	6060
gggttggact caagacgata gttaccggat aaggcgcagc ggtcgggctg aacgggggggt	6120
tcgtgcacac agcccagctt ggagcgaacg acctacaccg aactgagata cctacagcgt	6180
gagctatgag aaagcgccac gcttcccga gggagaaagg cggacaggta tccggtaagc	6240
ggcagggctg gaacaggaga gcgcacgagg gagcttccag ggggaaacgc ctggtatctt	6300
tatagtcctg tcgggtttcg ccacctctga cttgagcgtc gattttttgtg atgctcgtca	6360
ggggggcgga gcctatggaa aaacgccagc aacgcggcct ttttacgggt cctgggcttt	6420
tgctggcctt ttgctcacat gttctttcct gcgttatccc ctgattctgt ggataaccgt	6480
attaccgcct ttgagtggag tgataccgct cgccgcagcc gaacgaccga gcgcagcgag	6540
tcagtggagc aggaagcgga agagcgccca atacgcaaac cgctctctcc cgcgcgttgg	6600
ccgattcatt aatgcagctg gcacgacagg tttcccgaact ggaaagcggg cagtggagcgc	6660
aacgcaatta atgtgagtta gctcactcat taggcacccc aggcctttaca ctttatgctt	6720
ccggctcgta tgttgtgtgg aattgtgagc ggataacaat ttcacacagg aaacagctat	6780
gaccatgatt acgccaagct atttaggatga cactatagaa tactcaagct atgcatcaag	6840
cttggtagcg agctcggatc cactagtaac ggccgccagt gtgctggaat tcgccctta	6899

<210> 8
 <211> 3380
 <212> DNA
 <213> Artificial sequence

<220>
 <223> PCR product II

<400> 8	
cacacatcca gagctctatg aagagatggg tatcaaacc cccaagggag tcattcttta	60
cggcgctccc ggaaccggaa agacactgct ggccaaggcc gtcgccaacc agacttctgc	120
tacatttttg cgaatcgttg gatccgagct gatccaaaag tacttgggag acggtccccg	180
actgtgtcga cagattttcc agattgccgc agaacacgca ccgtccattg ttttcatcga	240
tgagattgac gctattggaa ccaaacgata cgagtcgacg tctggcggag agcgagaggt	300
gcagcggacc atgctggagc ttctgaacca gctggatgga ttcgacgacc gaggagacgt	360
caaggtaatt atggctacaa acaagattga gtcgctggac cctgcactga ttcgacctgg	420
tcgaatcgac cgaaagattc tgtttgagaa tcccgaactcc accaccaagc gaaagattat	480
gggcatccac acctccaaga tgaacctcaa cgacgatgtt gatctcgagg agtttggtc	540
ttccaaggat gaactttctg gagccgacat caaggccatg tgcaccgagg caggctctgct	600
tgctctgcga gagagacgaa tgcgggtcac tgctgaggat ttccgaaccg ctaaagagcg	660
ggtcatgaag aacaagggtg aggagaacct tgagggtctc tacctgtaag catagaagca	720
ttaacgtatg actataataa atacatcaat gaggtggagg ttgacgggga cttcttcgta	780

tacataactaa catctaacat ctacagtaga tcgaataact tgcaacggta catgccgtca	840
tagaaaagacg tttggtagaa aatgcctaata agagacaaca cacattccaa tacacagaca	900
gttacaacca gcagccacat tggtatataa atgtttacca agtgagccta accagtgggt	960
gtaagtcata catcatcatt cattatattag tcatgatcca tgaaatgttt atgcaatacg	1020
tttcacagtt cattgggtca gcttaaaact tgtatttggt atataagtta cgctagggat	1080
aacagggtaa tcataacttc gtatagcata cattatacga agttattctg aattccgccc	1140
agagagccat tgacgttctt tctaatttgg accgatagcc gtatagtcca gtctatctat	1200
aagttcaact aactcgtaac tattaccata acatatactt cactgccccca gataaggttc	1260
cgataaaaag ttctgcagac taaatttatt tcagtctcct cttcaccacc aaaatgccct	1320
cctacgaagc tcgagctaac gtccacaagt ccgcctttgc cgctcgagtg ctcaagctcg	1380
tggcagccaa gaaaaccaac ctgtgtgctt ctctggatgt taccaccacc aaggagctca	1440
ttgagcttgc cgataaggtc ggaccttatg tgtgcatgat caagacccat atcgacatca	1500
ttgacgactt cacctacgcc ggactgtgc tccccctcaa ggaacttgct cttaagcacg	1560
gtttcttcct gttcgaggac agaaagttcg cagatattgg caacactgtc aagcaccagt	1620
accggtgtca ccgaatcgcc gagtgggtccg atatcaccaa cgcccacggg gtacccggaa	1680
ccggaatcat tgctggcctg cgagctgggt ccgaggaaac tgtctctgaa cagaagaagg	1740
aggacgtctc tgactacgag aactcccagt acaaggagtt cctagtcccc tctcccaacg	1800
agaagctggc cagaggtctg ctcatgctgg ccgagctgtc ttgcaagggc tctctggcca	1860
ctggcgagta ctccaagcag accattgagc ttgcccgatc cgaccccgag tttgtggttg	1920
gcttcattgc ccagaaccga cctaagggcg actctgagga ctggcttatt ctgacccccg	1980
gggtgggtct tgacgacaag ggagacgctc tcggacagca gtaccgaact gttgaggatg	2040
tcatgtctac ccgaacggat atcataattg tcggccgagg tctgtacggc cagaaccgag	2100
atcctattga ggaggccaag cgataccaga aggttggtcg ggaggcttac cagaagatta	2160
actgttagag gttagactat ggatatgtaa ttttaactgtg tatatagaga gcgtgcaagt	2220
atggagcgct gttcagcttg tatgatggtc agacgacctg tctgatcgag tatgtatggt	2280
actgcacaac ctgtgtatcc gcatgggtctg tccaatgggg catgttggtg tgtttctcgg	2340
aattcgtata acttcgtata gcaggagtta tccgaagcga tatagggata acagggtaat	2400
atagtatata gctgtgtatg tggttaggggtg ggttttgggtg tggttgaaag gagtgccaga	2460
aaagagatcg gtctagcttt atcctctggc ctgcggctca cccagattt gaactttggg	2520
tttgtcgggc tagtctcggg gcgcgtgtgg gggagatgca tcaataaccg cataatagtg	2580
gtcccactgc aggtggttgg aggtggagct gaaactttta tttcctaata tcgtattcaa	2640
gctgtctcca aaggagcatt catcctcgca actcctcgga ctagctccaa aaggcatttt	2700
tagccgcgtc tgcgtacagg taagggatcc cccccacatt atccaccag cattagtctt	2760
gcgttatgta cactcaacag agttcgtcga ttgccgccga agcggacatc ttcgttgggt	2820

gagggaccag gcttgtggta tattaattgg agaggagggc cgagaggggtt ggcgagaagt	2880
tacaaattga actaggagta cacatagaat gatatacctt ctacttctac tgacgggtcgt	2940
agtcacaata cgtgctgtgt cacaatacgt gcgtgtgtac atctgagtta taacttgcac	3000
tgggttgtca gtgatgaacc cacagtgtga ttatgtcctg cccagtgtac aagtacagca	3060
ctattatggg tgttgcaccc tatccatcta tatacccacc atgttagccc cgtaagtga	3120
attgattccc ttcatgcgct ccacaagtac agtacatagt catcggcatg catattatat	3180
acctacagca tgtacagtat gtactgtaat agtgggagat cctacagtat ttgtagtgct	3240
ttcttggtagg acatgcatac ttgaccacag tgcgaaaaat atcgtacttg tacttaacca	3300
ctttttgtac ttttataacg tgcgtcaaag cctcttaatt gatgacgctc cagctattat	3360
tggtgcacct gaaggtcacc	3380

<210> 9
 <211> 20
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Primer

<400> 9	
gagtcgcaga ttcaggaaat	20

<210> 10
 <211> 20
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Primer

<400> 10	
tcaccttctg atcacggtgt	20